Dry powder inhalers with dual piercing members

ABSTRACT

A dry powder inhaler includes a dose container assembly having a dose container disk with opposing upper and lower surfaces, a first row of circumferentially spaced apart dose containers at a first radius and a second row of circumferentially spaced apart dose containers at a second radius. The dose containers have dry powder therein and are sealed via a first flexible sealant over apertures in the upper surface and a second flexible sealant over apertures in the lower surface. A piercing mechanism includes two reciprocating piercers that serially alternate between the two rows of dose containers in the dose container disk. A rotatable ramp disk includes first and second sets of circumferentially spaced-apart ramp elements in staggered, concentric relationship that are configured to move the first and second piercing members between retracted and extended positions.

RELATED APPLICATIONS

This application is a continuation application of U.S. patentapplication Ser. No. 12/566,724, filed Sep. 25, 2009, which claims thebenefit of and priority to U.S. Provisional Patent Application No.61/170,801, filed Apr. 20, 2009; U.S. Provisional Patent Application No.61/100,482, filed Sep. 26, 2008; and U.S. Provisional Patent ApplicationNo. 61/148,520, filed Jan. 30, 2009, the disclosures of which areincorporated herein by reference as if set forth in their entireties.

FIELD OF THE INVENTION

The present invention relates to inhalers, and may be particularlysuitable for dry powder inhalers.

BACKGROUND

Dry powder inhalers (DPIs) are an alternative to pMDI (pressurizedmetered dose inhaler) devices for delivering drug aerosols without usingpropellants. Typically, DPIs are configured to deliver a powdered drugor drug mixture that includes an excipient and/or other ingredients.Generally described, known single and multiple dose dry powder DPIdevices use: (a) individual pre-measured doses in blisters containingthe drug, which can be inserted into the device prior to dispensing; or(b) bulk powder reservoirs which are configured to administer successivequantities of the drug to the patient via a dispensing chamber whichdispenses the proper dose.

In operation, DPI devices strive to administer a uniform aerosoldispersion amount in a desired physical form of the dry powder (such asa particulate size or sizes) into a patient's airway and direct it to adesired internal deposit site(s).

There remains a need for alternative inhalers and/or dose containmentdevices that can be used to deliver medicaments.

SUMMARY

Embodiments of the present invention provide dry powder inhalers withreciprocating inner and outer piercing mechanisms that facilitate theuse of dose rings or disks having dose containers arranged in concentricrows. According to some embodiments, a dry powder inhaler includes adose container disk having a plurality of circumferentially spaced apartdry powder dose containers arranged in first and second concentric rowsof different radius, and a piercing mechanism that is configured tosequentially open a dry powder dose container on the first row then opena dry powder dose container on the second row. The piercing mechanismincludes first and second elongate piercing members in adjacent radiallyspaced-apart relationship. Each piercing member is capable of reciprocalmovement between piercing and non-piercing positions, and includes adistal piercing portion and a proximal head portion. The first piercingmember is configured to pierce the sealant of a dose container in thefirst row, and the second piercing member is configured to pierce thesealant of a dose container in the second row.

According to some embodiments, a dry powder inhaler includes a dosecontainer disk having opposing upper and lower primary surfaces, a firstrow of circumferentially spaced apart dose containers at a first radiusand a second row of circumferentially spaced apart dose containers at asecond radius so that the first and second rows are concentric withrespect to a center of the disk. The dose containers have dry powdertherein. A first flexible sealant resides over apertures in the uppersurface, and a second flexible sealant resides over apertures in thelower surface to contain the powder within the dose containers.

A piercing mechanism is operably associated with the dose container diskand is configured to pierce the first and second sealants that seal adose container. The piercing mechanism includes two reciprocatingpiercers that serially alternate between the two rows of dose containersin the dose container disk. Each elongate piercing member is extendedand retracted to pierce the first and second sealants of a dosecontainer in a respective row. Each elongate piercing member includes adistal piercing portion and a proximal head portion. In someembodiments, the distal piercing portion can be a solid piercerconfigured to pierce the sealants. In some embodiments, the distalpiercing portion can be a corkscrew piercer configured to pierce thesealants with a straight vertical non-rotational movement. In someembodiments, the distal piercing portion can have a fluted piercer, forexample with three or four lobes, that is configured to pierce thesealants.

Each elongate piercing member is capable of reciprocal movement betweenpiercing and non-piercing positions. In the piercing position, thepiercing member distal piercing portion extends through the first andsecond sealants of a dose container. In a retracted position, the distalpiercing portion is retracted above a dose container, such that the dosecontainer is free to rotate. A biasing member is configured to urge eachof the piercing members toward retracted positions.

A rotatable ramp disk includes first and second sets ofcircumferentially spaced-apart ramp elements in staggered, concentricrelationship. The ramp disk rotates only in one direction, and is drivenby an actuator mechanism, which is moved forward by the user, andreturned backward by the user action of closing the mouthpiece cover ofthe inhaler. When the ramp disk is rotated as a result of the usermoving the actuator mechanism, the first set of ramp elements areconfigured to move the first piercing member between retracted andextended positions, and the second set of ramp elements are configuredto move the second piercing member between retracted and extendedpositions. The ramp elements are staggered such that piercing alternatesbetween dose containers in the first and second rows. Each ramp elementin the first and second sets includes a first inclined portion, aplateau portion, a second inclined portion, and a shelf portion.

The actuator mechanism is movable between first and second positions bya user. Movement of the actuator from the first position to the secondposition causes the ramp disk to rotate such that a ramp element in thefirst set causes the first piercing member to pierce the sealants overand under a dose container in the first row. Subsequent movement of theactuator from the first position to the second position (i.e., the nexttime the inhaler is used) causes the ramp disk to rotate such that aramp element in the second set causes the second piercing member topierce the sealants over and under a dose container in the second row.This alternating piercing scheme is repeated as the inhaler is used. Insome embodiments, movement of the actuator from the first position tothe second position causes a piercing member to pierce the sealants overand under a dose container, and then partially retract therefrom.

Inhalers, according to embodiments of the present invention havenumerous advantages over conventional inhalers. For example, the use oftwo piercing members takes away the need to tightly control the positionand actions of a single, moving piercer. Moreover, by using two piercingmembers, wear can be significantly reduced for each piercing member. Assuch, a less expensive material may be utilized for the piercing membersthan may otherwise be necessary if only a single piercing member were tobe utilized. In addition, the configuration of the two piercing membersallows more flexibility for the design of a spring used to urge thepiercing members to a retracted position. For example, the spring is notrequired to be positioned under the piercing members. As such, inhalerdevices with less height requirements than conventional inhaler devicescan be achieved.

Other advantages of inhaler devices according to embodiments of thepresent invention is provided by the use of a separate ramp disk andactuator mechanism. Because indexing of a dose container assembly isdriven by the ramp disk, the indexing mechanism can be moved to theinterior of the inhaler where more space is available, thereby helpingto reduce the overall size of the inhaler. Because the ramp disk andactuator mechanism are separate components, the material selection ofeach can be optimized. For example, material with better frictionproperties can be selected for the ramp disk, and materials withstrength and cosmetic features can be selected for the actuatormechanism.

It is noted that aspects of the invention described with respect to oneembodiment may be incorporated in a different embodiment although notspecifically described relative thereto. That is, all embodiments and/orfeatures of any embodiment can be combined in any way and/orcombination. Applicant reserves the right to change any originally filedclaim or file any new claim accordingly, including the right to be ableto amend any originally filed claim to depend from and/or incorporateany feature of any other claim although not originally claimed in thatmanner. These and other objects and/or aspects of the present inventionare explained in detail in the specification set forth below.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a front perspective view of an inhaler with a cover,according to some embodiments of the present invention, and where thecover is in a closed position.

FIG. 1B is a front perspective view of the inhaler of FIG. 1A with thecover moved to an open or operational position.

FIG. 1C is a front perspective view of the inhaler of FIG. 1Billustrating a user-accessible actuator lever moved to a secondposition.

FIG. 2A is a top perspective view of a dose container assembly accordingto some embodiments of the present invention.

FIG. 2B is an exploded view of the assembly shown in FIG. 2A.

FIG. 2C is a partial cutaway view of airway channels aligned with twodose containers according to some embodiments of the present invention.

FIG. 2D is a top perspective view of another exemplary dose containerassembly according to some embodiments of the present invention.

FIG. 2E is an exploded view of the dose container assembly shown in FIG.2D according to embodiments of the present invention.

FIG. 3A is a top perspective view of a dose container ring according tosome embodiments of the present invention.

FIG. 3B is a top perspective view of a dose container ring according tosome other embodiments of the present invention.

FIG. 3C is a partial cutaway view of a single dose container accordingto some embodiments of the present invention.

FIG. 3D is a partial cutaway view of a single dose container accordingto some embodiments of the present invention.

FIG. 4A is a greatly enlarged top perspective view of a lower airwaydisk according to some embodiments of the present invention.

FIG. 4B is a top view of a lower airway disk according to someembodiments of the present invention.

FIG. 4C is a bottom view of the lower airway disk shown in FIG. 4B.

FIG. 5A is a greatly enlarged top perspective view of an upper airwaydisk according to some embodiments of the present invention.

FIG. 5B is a greatly enlarged perspective view of an upper airway diskaccording to other embodiments of the present invention.

FIG. 6 is a greatly enlarged partial view of the dose container assemblyshown in FIG. 2A according to embodiments of the present invention.

FIGS. 7A-7C are partial cutaway views of a dose container assembly in aninhaler cooperating with a piercing mechanism having a three-stageoperation sequence according to some embodiments of the presentinvention.

FIG. 8A is a top view of a dose container ring according to someembodiments of the present invention.

FIG. 8B is a partial enlarged fragmentary view of the ring shown in FIG.8A.

FIG. 9 is a side view of the ring shown in FIG. 8A.

FIG. 10A is a cutaway, partial perspective view of an inhaler having areciprocating dual piercing mechanism, according to some embodiments ofthe present invention.

FIG. 10B is a cutaway, partial perspective view of an inhaler having areciprocating dual piercing mechanism, according to some embodiments ofthe present invention.

FIG. 11A is a top perspective view of the inhaler of FIG. 10A with thecover and upper and lower housing portions removed.

FIG. 11B is a top perspective view of the inhaler of FIG. 10B with thecover and upper and lower housing portions removed.

FIG. 11C is a top plan view of the inhaler of FIG. 10B with the cover 11displayed transparently for clarity and illustrating ratchet arms in thecover that cooperate with teeth in the ramp disk.

FIG. 12A is a top perspective view of the inhaler of FIG. 10A with theramp disk removed therefrom, according to some embodiments of thepresent invention.

FIG. 12B is a top perspective view of the inhaler of FIG. 10B with theramp disk removed therefrom, according to some embodiments of thepresent invention.

FIG. 13A is a bottom perspective view of the ramp disk of the inhaler ofFIG. 10A, according to some embodiments of the present invention.

FIG. 13B is a bottom perspective view of the ramp disk of the inhaler ofFIG. 10B, according to some embodiments of the present invention.

FIG. 13C is a top perspective view of the ramp disk of FIG. 13B,according to some embodiments of the present invention.

FIG. 14A is a bottom, cutaway perspective view of the inhaler of FIG.10A illustrating the dose disk indexing mechanism, according to someembodiments of the present invention.

FIG. 14B is a partial plan view of the lower disk of the dose containerassembly and illustrating dose indicia thereon, according to someembodiments of the present invention.

FIG. 14C is a bottom, cutaway perspective view of the inhaler of FIG.10B illustrating the dose disk indexing mechanism, according to someembodiments of the present invention.

FIG. 14D is an enlarged, partial plan view of the inhaler of FIG. 14Cillustrating the window aperture centered over dose indicia thatindicates that 60 doses are remaining.

FIG. 14E is an enlarged, partial plan view of the inhaler of FIG. 14Cillustrating the window aperture centered over dose indicia thatindicates that no (zero) doses are remaining.

FIG. 15A is a top, cutaway perspective view of the inhaler of FIG. 10Aillustrating the dose disk indexing mechanism in relation to a dosecontainer assembly, according to some embodiments of the presentinvention.

FIG. 15B is a top, cutaway perspective view of the inhaler of FIG. 10Billustrating the dose disk indexing mechanism in relation to a dosecontainer assembly, according to some embodiments of the presentinvention.

FIG. 15C is an exploded side perspective view of components of theindexing mechanism of the inhaler of FIG. 10B.

FIG. 16A is a bottom, cutaway perspective view of the inhaler of FIG.10A illustrating a dose disk biasing post associated with theuser-accessible actuator for biasing the dose disk toward themouthpiece, according to some embodiments of the present invention.

FIG. 16B is a bottom, cutaway perspective view of the inhaler of FIG.10B illustrating a dose disk biasing post associated with theuser-accessible actuator for biasing the dose disk toward themouthpiece, according to some embodiments of the present invention.

FIGS. 17A-17E are top, cutaway views, with partial transparent layers ormembers/disks for clarity, of the inhaler of FIG. 10A that illustrate anexemplary sequence of operations thereof, according to some embodimentsof the present invention.

FIGS. 18A-18C are top, cutaway views, with partial transparent layers ormembers/disks for clarity, of the inhaler of FIG. 10B that illustrate anexemplary sequence of operations thereof, according to some embodimentsof the present invention.

FIG. 19A is an enlarged partial section view of a piercing memberaccording to some embodiments of the present invention.

FIG. 19B is an enlarged partial section view of a piercing membersimilar to that shown in FIG. 19A, according to some embodiments of thepresent invention.

FIG. 19C is a partial front schematic view of a piercing member with afluted configuration, according to some embodiments of the presentinvention.

FIG. 19D is an end view of the device shown in FIG. 19C.

FIG. 19E is a partial front schematic view of another fluted piercerconfiguration according to some embodiments of the present invention.

FIG. 19F is an end view of an exemplary four lobe fluted piercer,according to some embodiments of the present invention.

FIG. 20 is an enlarged partial section view of an inhaler havinggenerally “U” shaped inhalation flow paths for each dose according toembodiments of the present invention.

DETAILED DESCRIPTION

The present invention will now be described more fully hereinafter withreference to the accompanying figures, in which embodiments of theinvention are shown. This invention may, however, be embodied in manydifferent forms and should not be construed as limited to theembodiments set forth herein. Like numbers refer to like elementsthroughout. In the figures, certain layers, components or features maybe exaggerated for clarity, and broken lines illustrate optionalfeatures or operations unless specified otherwise. In addition, thesequence of operations (or steps) is not limited to the order presentedin the figures and/or claims unless specifically indicated otherwise.Features described with respect to one figure or embodiment can beassociated with another embodiment of figure although not specificallydescribed or shown as such.

It will be understood that when a feature, such as a layer, region orsubstrate, is referred to as being “on” another feature or element, itcan be directly on the other feature or element or intervening featuresand/or elements may also be present. In contrast, when an element isreferred to as being “directly on” another feature or element, there areno intervening elements present. It will also be understood that, when afeature or element is referred to as being “connected”, “attached” or“coupled” to another feature or element, it can be directly connected,attached or coupled to the other element or intervening elements may bepresent. In contrast, when a feature or element is referred to as being“directly connected”, “directly attached” or “directly coupled” toanother element, there are no intervening elements present. Althoughdescribed or shown with respect to one embodiment, the features sodescribed or shown can apply to other embodiments.

The terminology used herein is for the purpose of describing particularembodiments only and is not intended to be limiting of the invention. Asused herein, the singular forms “a”, “an” and “the” are intended toinclude the plural forms as well, unless the context clearly indicatesotherwise. It will be further understood that the terms “comprises”and/or “comprising,” when used in this specification, specify thepresence of stated features, steps, operations, elements, and/orcomponents, but do not preclude the presence or addition of one or moreother features, steps, operations, elements, components, and/or groupsthereof. As used herein, the term “and/or” includes any and allcombinations of one or more of the associated listed items.

Spatially relative terms, such as “under”, “below”, “lower”, “over”,“upper” and the like, may be used herein for ease of description todescribe one element or feature's relationship to another element(s) orfeature(s) as illustrated in the figures. It will be understood that thespatially relative terms are intended to encompass differentorientations of the device in use or operation in addition to theorientation depicted in the figures. For example, if a device in thefigures is inverted, elements described as “under” or “beneath” otherelements or features would then be oriented “over” the other elements orfeatures. Thus, the exemplary term “under” can encompass both anorientation of over and under. The device may be otherwise oriented(rotated 90 degrees or at other orientations) and the spatially relativedescriptors used herein interpreted accordingly. Similarly, the terms“upwardly”, “downwardly”, “vertical”, “horizontal” and the like are usedherein for the purpose of explanation only unless specifically indicatedotherwise.

It will be understood that although the terms first and second are usedherein to describe various regions, layers and/or sections, theseregions, layers and/or sections should not be limited by these terms.These terms are only used to distinguish one region, layer or sectionfrom another region, layer or section. Thus, a first region, layer orsection discussed below could be termed a second region, layer orsection, and similarly, a second region, layer or section discussedbelow could be termed a first region, layer or section without departingfrom the teachings of the present invention. Like numbers refer to likeelements throughout.

Unless otherwise defined, all terms (including technical and scientificterms) used herein have the same meaning as commonly understood by oneof ordinary skill in the art to which this invention belongs. It will befurther understood that terms, such as those defined in commonly useddictionaries, should be interpreted as having a meaning that isconsistent with their meaning in the context of the specification andrelevant art and should not be interpreted in an idealized or overlyformal sense unless expressly so defined herein. Well-known functions orconstructions may not be described in detail for brevity and/or clarity.

In the description of the present invention that follows, certain termsare employed to refer to the positional relationship of certainstructures relative to other structures. As used herein, the term“front” or “forward” and derivatives thereof refer to the general orprimary direction that the dry powder travels to be dispensed to apatient from a dry powder inhaler; this term is intended to besynonymous with the term “downstream,” which is often used inmanufacturing or material flow environments to indicate that certainmaterial traveling or being acted upon is farther along in that processthan other material. Conversely, the terms “rearward” and “upstream” andderivatives thereof refer to the direction opposite, respectively, theforward or downstream direction. The term “deagglomeration” and itsderivatives refer to processing dry powder in the inhaler airflow pathto inhibit the dry powder from remaining or becoming agglomerated orcohesive during inspiration.

The inhalers and methods of the present invention may be particularlysuitable for holding a partial or bolus dose or doses of one or moretypes of particulate dry powder substances that are formulated for invivo inhalant dispersion (using an inhaler) to subjects, including, butnot limited to, animal and, typically, human subjects. The inhalers canbe used for nasal and/or oral (mouth) respiratory inhalation delivery,but are typically oral inhalers.

The terms “sealant”, “sealant layer” and/or “sealant material” includesconfigurations that have at least one layer of at least one material andcan be provided as a continuous layer that covers the entire uppersurface and/or lower surface or may be provided as strips or pieces tocover portions of the device, e.g., to reside over at least a target oneor more of the dose container apertures. Thus, terms “sealant” and“sealant layer” includes single and multiple layer materials, typicallycomprising at least one foil layer. The sealant or sealant layer can bea thin multi-layer laminated sealant material with elastomeric and foilmaterials. The sealant layer can be selected to provide drug stabilityas they may contact the dry powder in the respective dose containers.

The term “reciprocating” means the piercing members travel up and downto open respective dose containers.

The sealed dose containers can be configured to inhibit oxygen andmoisture penetration to provide a sufficient shelf life.

The term “primary surface” refers to a surface that has a greater areathan another surface and the primary surface can be substantially planaror may be otherwise configured. For example, a primary surface caninclude protrusions or recessions, such as where some blisterconfigurations are used. Thus, a disk can have upper and lower primarysurfaces and a minor surface (e.g., a wall with a thickness) thatextends between and connects the two.

The dry powder substance may include one or more active pharmaceuticalconstituents as well as biocompatible additives that form the desiredformulation or blend. As used herein, the term “dry powder” is usedinterchangeably with “dry powder formulation” and means that the drypowder can comprise one or a plurality of constituents or ingredientswith one or a plurality of (average) particulate size ranges. The term“low-density” dry powder means dry powders having a density of about 0.8g/cm³ or less. In particular embodiments, the low-density powder mayhave a density of about 0.5 g/cm³ or less. The dry powder may be a drypowder with cohesive or agglomeration tendencies.

The term “filling” means providing a bolus or sub-bolus metered amountof dry powder. Thus, the respective dose container is not required to bevolumetrically full.

In any event, individual dispensable quantities of dry powderformulations can comprise a single ingredient or a plurality ofingredients, whether active or inactive. The inactive ingredients caninclude additives added to enhance flowability or to facilitateaerosolization delivery to the desired target. The dry powder drugformulations can include active particulate sizes that vary. The devicemay be particularly suitable for dry powder formulations havingparticulates which are in the range of between about 0.5-50 μm,typically in the range of between about 0.5 μm-20.0 μm, and moretypically in the range of between about 0.5 μm-8.0 μm. The dry powderformulation can also include flow-enhancing ingredients, which typicallyhave particulate sizes that may be larger than the active ingredientparticulate sizes. In certain embodiments, the flow-enhancingingredients can include excipients having particulate sizes on the orderof about 50-100 μm. Examples of excipients include lactose andtrehalose. Other types of excipients can also be employed, such as, butnot limited to, sugars which are approved by the United States Food andDrug Administration (“FDA”) as cryoprotectants (e.g., mannitol) or assolubility enhancers (e.g., cyclodextrine) or other generally recognizedas safe (“GRAS”) excipients.

“Active agent” or “active ingredient” as described herein includes aningredient, agent, drug, compound, or composition of matter or mixture,which provides some pharmacologic, often beneficial, effect. Thisincludes foods, food supplements, nutrients, drugs, vaccines, vitamins,and other beneficial agents. As used herein, the terms further includeany physiologically or pharmacologically active substance that producesa localized and/or systemic effect in a patient.

The active ingredient or agent that can be delivered includesantibiotics, antiviral agents, anepileptics, analgesics,anti-inflammatory agents and bronchodilators, and may be inorganicand/or organic compounds, including, without limitation, drugs which acton the peripheral nerves, adrenergic receptors, cholinergic receptors,the skeletal muscles, the cardiovascular system, smooth muscles, theblood circulatory system, synoptic sites, neuroeffector junctionalsites, endocrine and hormone systems, the immunological system, thereproductive system, the skeletal system, autacoid systems, thealimentary and excretory systems, the histamine system, and the centralnervous system. Suitable agents may be selected from, for example andwithout limitation, polysaccharides, steroids, hypnotics and sedatives,psychic energizers, tranquilizers, anticonvulsants, muscle relaxants,anti-Parkinson agents, analgesics, anti-inflammatories, musclecontractants, antimicrobials, antimalarials, hormonal agents includingcontraceptives, sympathomimetics, polypeptides and/or proteins (capableof eliciting physiological effects), diuretics, lipid regulating agents,antiandrogenic agents, antiparasitics, neoplastics, antineoplastics,hypoglycemics, nutritional agents and supplements, growth supplements,fats, antienteritis agents, electrolytes, vaccines and diagnosticagents.

The active agents may be naturally occurring molecules or they may berecombinantly produced, or they may be analogs of the naturallyoccurring or recombinantly produced active agents with one or more aminoacids added or deleted. Further, the active agent may comprise liveattenuated or killed viruses suitable for use as vaccines. Where theactive agent is insulin, the term “insulin” includes natural extractedhuman insulin, recombinantly produced human insulin, insulin extractedfrom bovine and/or porcine and/or other sources, recombinantly producedporcine, bovine or other suitable donor/extraction insulin and mixturesof any of the above. The insulin may be neat (that is, in itssubstantially purified form), but may also include excipients ascommercially formulated. Also included in the term “insulin” are insulinanalogs where one or more of the amino acids of the naturally occurringor recombinantly produced insulin has been deleted or added.

It is to be understood that more than one active ingredient or agent maybe incorporated into the aerosolized active agent formulation and thatthe use of the term “agent” or “ingredient” in no way excludes the useof two or more such agents. Indeed, some embodiments of the presentinvention contemplate administering combination drugs that may be mixedin situ.

Examples of diseases, conditions or disorders that may be treatedaccording to embodiments of the invention include, but are not limitedto, asthma, COPD (chronic obstructive pulmonary disease), viral orbacterial infections, influenza, allergies, cystic fibrosis, and otherrespiratory ailments as well as diabetes and other insulin resistancedisorders. The dry powder inhalation may be used to deliverlocally-acting agents such as antimicrobials, protease inhibitors, andnucleic acids/oligionucleotides as well as systemic agents such aspeptides like leuprolide and proteins such as insulin. For example,inhaler-based delivery of antimicrobial agents such as antitubercularcompounds, proteins such as insulin for diabetes therapy or otherinsulin-resistance related disorders, peptides such as leuprolideacetate for treatment of prostate cancer and/or endometriosis andnucleic acids or ogligonucleotides for cystic fibrosis gene therapy maybe performed. See e.g. Wolff et al., Generation of Aerosolized Drugs, J.Aerosol. Med. pp. 89-106 (1994). See also U.S. Patent ApplicationPublication No. 20010053761, entitled Method for AdministeringASPB28-Human Insulin and U.S. Patent Application Publication No.20010007853, entitled Method for Administering Monomeric InsulinAnalogs, the contents of which are hereby incorporated by reference asif recited in full herein.

Typical dose amounts of the unitized dry powder mixture dispersed in theinhalers may vary depending on the patient size, the systemic target,and the particular drug(s). The dose amounts and type of drug held by adose container system may vary per dose container or may be the same. Insome embodiments, the dry powder dose amounts can be about 100 mg orless, typically less than 50 mg, and more typically between about 0.1 mgto about 30 mg.

In some embodiments, such as for pulmonary conditions (i.e., asthma orCOPD), the dry powder can be provided as about 5 mg total weight (thedose amount may be blended to provide this weight). A conventionalexemplary dry powder dose amount for an average adult is less than about50 mg, typically between about 10-30 mg and for an average adolescentpediatric subject is typically from about 5-10 mg. A typical doseconcentration may be between about 1-5%. Exemplary dry powder drugsinclude, but are not limited to, albuterol, fluticasone, beclamethasone,cromolyn, terbutaline, fenoterol, β-agonists (including long-actingβ-agonists), salmeterol, formoterol, cortico-steroids andglucocorticoids.

In certain embodiments, the administered bolus or dose can be formulatedwith an increase in concentration (an increased percentage of activeconstituents) over conventional blends. Further, the dry powderformulations may be configured as a smaller administrable dose comparedto the conventional 10-25 mg doses. For example, each administrable drypowder dose may be on the order of less than about 60-70% of that ofconventional doses. In certain particular embodiments, using thedispersal systems provided by certain embodiments of the DPIconfigurations of the instant invention, the adult dose may be reducedto under about 15 mg, such as between about 10 μg-10 mg, and moretypically between about 50 μg-10 mg. The active constituent(s)concentration may be between about 5-10%. In other embodiments, activeconstituent concentrations can be in the range of between about 10-20%,20-25%, or even larger. In particular embodiments, such as for nasalinhalation, target dose amounts may be between about 12-100 μg.

In certain particular embodiments, during inhalation, the dry powder ina particular drug compartment or blister may be formulated in highconcentrations of an active pharmaceutical constituent(s) substantiallywithout additives (such as excipients). As used herein, “substantiallywithout additives” means that the dry powder is in a substantially pureactive formulation with only minimal amounts of othernon-biopharmacological active ingredients. The term “minimal amounts”means that the non-active ingredients may be present, but are present ingreatly reduced amounts, relative to the active ingredient(s), such thatthey comprise less than about 10%, and preferably less than about 5%, ofthe dispensed dry powder formulation, and, in certain embodiments, thenon-active ingredients are present in only trace amounts.

In some embodiments, the unit dose amount of dry powder held in arespective drug compartment or dose container is less than about 10 mg,typically about 5 mg of blended drug and lactose or other additive(e.g., 5 mg LAC), for treating pulmonary conditions such as asthma.Insulin may be provided in quantities of about 4 mg or less, typicallyabout 3.6 mg of pure insulin. The dry powder may be inserted into a dosecontainer/drug compartment in a “compressed” or partially compressedmanner or may be provided as free flowing particulates.

Some embodiments of the invention are directed to inhalers that candeliver multiple different drugs for combination delivery. Thus, forexample, in some embodiments, some or all of the dose containers mayinclude two different drugs or different dose containers may containdifferent drugs configured for dispensing substantially concurrently.

In some embodiments, a dose container disk for an inhaler device mayinclude a first row of circumferentially spaced apart dose containers ata first radius and a second row of circumferentially spaced apart dosecontainers at a second radius so that the first and second rows aresubstantially concentric. In some embodiments, the same drug may beincluded in all of the dose containers. In other embodiments, a firstdrug may be included within the dose containers of the first row, and asecond drug, different from the first drug, may be included within thedose containers of the second row.

The inhalers can be configured to provide any suitable number of doses,typically between about 30-120 doses, and more typically between about30-60 doses. The inhalers can deliver one drug or a combination ofdrugs. In some embodiments, the inhalers can provide between about 30-60doses of two different drugs (in the same or different unit amounts),for a total of between about 60-120 individual unit doses, respectively.The inhaler can provide between a 30 day to a 60 day (or even greater)supply of medicine. In some embodiments, the inhalers can be configuredto hold about 60 doses of the same drug or drug combination, in the sameor different unit amounts, which can be a 30 day supply (for a twice perday dosing) or a 60 day supply for single daily treatments.

Certain embodiments may be particularly suitable for dispensingmedication to respiratory patients, diabetic patients, cystic fibrosispatients, or for treating pain. The inhalers may also be used todispense narcotics, hormones and/or infertility treatments.

The dose container assembly and inhaler may be particularly suitable fordispensing medicament for the treatment of respiratory disorders.Appropriate medicaments may be selected from, for example, analgesics,e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine;anginal preparations, e.g., diltiazem; antiallergics, e.g.,cromoglycate, ketotifen or nedocromil; antiinfectives e.g.,cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclinesand pentamidine; antihistamines, e.g., methapyrilene;anti-inflammatories, e.g., beclomethasone dipropionate, fluticasonepropionate, flunisolide, budesonide, rofleponide, mometasone furoate ortriamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators,e.g., albuterol, salmeterol, ephedrine, adrenaline, fenoterol,formoterol, isoprenaline, metaproterenol, phenylephrine,phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline,isoetharine, tulobuterol, or (−)-4-amino-3, 5-dichloro-{acute over(α)}-[[6-[2-(2-pyridinyl) ethoxy]hexyl]methyl] benzenemethanol;diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium,tiotropium, atropine or oxitropium;

hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines,e.g., aminophylline, choline theophyllinate, lysine theophyllinate ortheophylline; therapeutic proteins and peptides, e.g., insulin orglucagon. It will be clear to a person of skill in the art that, whereappropriate, the medicaments may be used in the form of salts, (e.g., asalkali metal or amine salts or as acid addition salts) or as esters(e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimizethe activity and/or stability of the medicament.

Some particular embodiments of the dose container assembly and/orinhaler include medicaments that are selected from the group consistingof: albuterol, salmeterol, fluticasone propionate and beclometasonedipropionate and salts or solvates thereof, e.g., the sulphate ofalbuterol and the xinafoate of salmeterol. Medicaments can also bedelivered in combinations. Examples of particular formulationscontaining combinations of active ingredients include those that containsalbutamol (e.g., as the free base or the sulphate salt) or salmeterol(e.g., as the xinafoate salt) in combination with an anti-inflammatorysteroid such as a beclomethasone ester (e.g., the dipropionate) or afluticasone ester (e.g., the propionate).

Some attributes of DPI devices, according to embodiments of the presentinvention, can be: 1) the ability to protect the dry powder frommoisture ingress; 2) the number of doses contained within the inhaler;and 3) the overall size of the inhaler. In addition, it may beadvantageous to fit the largest practical number of doses within thesmallest possible inhaler. However, it may be necessary for individualdoses to be spaced apart from each other to allow sufficient seal areaand material thickness for moisture protection of the powder. Onesolution may be to use a dose ring with dose containers spacedequidistant from each other at two different radii, also referred to asa “staggered concentric” arrangement of doses.

Unfortunately, a challenge with a staggered concentric dose ring can behow to access each dose container for opening and inhalation. If all ofthe outer dose containers are opened first, followed by all inner dosecontainers, this may require an indexing device that will index a “halfstep” in order to effect the transition from the outer to inner ring ofdose containers, but index a “full step” for all other dose containers.This indexing functionality may be difficult to achieve in inhalerdevices. An alternative may be to create dose rings with a specialarrangement of dose containers on the dose ring. Unfortunately, this maycomplicate the automated handling and filling of the powder into thedose ring.

Turning now to the figures, FIGS. 1A-1C illustrate an example of amulti-dose inhaler 10 with a cover 11, inhalation port 10 p, and upperand lower housing portions 12, 13. However, this inhaler configurationis shown merely for completeness and embodiments of the invention arenot limited to this inhaler configuration as other form factors, coversand inhalation port configurations may be used. In FIG. 1A the cover 11is in a closed position. In FIG. 1B the cover 11 has been moved to anopen or operational position. FIG. 1C illustrates the user lever 320 ofan actuator mechanism 306 moved from a first position (FIG. 1B) to asecond position, as will be described below.

FIG. 2A illustrates a dose container assembly 20 for use within themulti-dose inhaler 10. The dose container assembly 20 includes a dosering or disk 30 having a plurality of dose containers 30 c. As shown inFIGS. 2B and 2E, in some embodiments, the dose ring or disk 30 caninclude a plurality of circumferentially spaced apart through apertures30 a that forms a portion of the dose containers 30 c. As shown in FIG.2E, the dose containers 30 c can be defined by dose container apertures30 a and upper and lower sealants 36,37.

As shown, the dose container assembly 20 includes a lower airway disk 40and an upper airway disk 50. In other embodiments, the dose containerassembly 20 can include the dose container disk 30 and only one of thelower airway disk 40 or the upper airway disk 50. In such aconfiguration, another type of airway can be used for the other side ofthe disk 30, such as, but not limited to, a fixed or “global” upper orlower airway can be used with the individual airways provided by eitheran upper or lower airway disk 50, 40. Also, it is contemplated that theupper and lower airway disks 50, 40 described herein can be reversed fornormal operation (or inadvertently for atypical operation) so that thelower airway disk is the upper airway disk and the upper airway disk isthe lower airway disk.

As shown in FIGS. 2A and 2B, the lower and upper airway disks 40, 50,respectively, include a plurality of circumferentially spaced apartairway channels 41, 51, respectively. Typically, the disks 40, 50include one channel 41, 51 for one dose container 30 c. However, inother embodiments, as shown, for example, in FIG. 2C, a respectiveairway channel 51, 41 from one or both of the disks 50′, 40′ can be incommunication with two different dose containers 30 c. Thisconfiguration will allow for (simultaneous) combination delivery of drypowder from two containers in a respective airway channel pair (orsingle) or can allow one dose container 30 c ₁ to release dry powder tothe airway channel 41 and/or 51, then be used again later for the otherdose container 30 c ₂. Thus, embodiments of the invention allow for someor all airway channels 41, 51 to be used once or twice. Also, whileembodiments of the invention are illustrated as releasing only a dosefrom a single dose container 30 c during one delivery, other embodimentsallow the inhalers to dispense a combination drug so that two or moredose containers 30 c may use a respective airway channel 41, 51 fordelivery.

In some embodiments, the airway channels 41, 51 can define airways thatare not able to release dry powder residing in a respective airwaychannel to a user once the inhaler is indexed again to another positionso that the respective airway channel is no longer in communication withthe inhalation port 10 p. The channels can be configured to have “sinktraps” to inhibit spillage according to some embodiments of the presentinvention to provide overdose protection (unless the dual useconfiguration is used whereby only a single other dose may be releasedusing that airway channel(s) as noted above).

Where two airway disks are used, e.g., both the lower and upper disks40, 50, the inhaler device 10 can be configured to operate even wheninverted and have the same overdose protection feature. Spillage of drypowder from the dose container 30 c as the dose container 30 c is openedcan be influenced by gravity. For example, for a conventional obround orelliptical mouthpiece shape, there are two primary device orientations(right-side-up and upside-down), embodiments of the invention allow foroperation of the inhaler device in both orientations. In the embodimentshown, for example, in FIG. 2A, this can be accomplished by having anindividual airway section for a respective dose container 30 c (or dosecontainers where combination drug delivery is desired) both above andbelow the target corresponding dose container(s) 30 c.

FIGS. 2A, 2D and 3A illustrate that the dose container disk 30 caninclude 60 dose containers 30 c while FIG. 3B illustrates that the dosecontainer disk 30 can include 30 dose containers 30 c. Greater or lessernumbers of dose containers may be used. FIG. 2E illustrates that sealantlayers 36, 37 may be configured as annular flat rings as shown and canbe used to seal the top and bottom surfaces of the dose disk 30. Thesealant layers 36, 37 can have the same or different material(s) and mayinclude foil, polymer(s) and/or elastomer(s), or other suitable materialor combinations of materials, including laminates. Typically, thesealant layers 36, 37 are thin flexible sealant layers comprising foil.The sealant layers 36, 37 (where used) may be provided as asubstantially continuous ring as shown in FIG. 2E or may be attached tothe dose container disk 30 as individual strips or spots of sealant thatcan be placed over and under the apertures 30 a. In other embodiments,sealant layers may be provided on only one primary surface of the dosedisk 30, and the apertures 30 a may be closed on one side rather thanhave through apertures (not shown). In yet other embodiments, the dosedisk 30 can have a blister configuration.

FIGS. 2B, 3A and 3B also illustrate that the dose container disk 30 caninclude at least one indexing notch 34, shown as a plurality ofcircumferentially spaced apart indexing notches 34. To assemble theassembly 20, a tab on one of the airway disks 40, 50, typically thelower disk 40, includes a radially extending tab 45 (FIG. 4A) thataligns with and engages one of those notches 34 to position the channels41, 51 in alignment with the dose containers 30 c. Other alignment meansmay be used including the reverse of the notch and tab configurationdescribed (e.g., the airway disk can have the notch and the dosecontainer disk can have the tab).

As shown in FIGS. 2B, 3A and 3B, the dose containers 30 c may bearranged so that they are circumferentially spaced apart in one or morerows. As shown in FIG. 3A, the dose containers 30 c are arranged instaggered concentric rows, a front row 31 at a first radius from acenter of the disk and a back row 32 at a second different radius. Asshown in FIG. 3A dose containers 30 c on each respective row are spacedapart a distance “D” and the offset of the centerlines of those on theback row to those on the front row is “D/2”. The dose container disk 30can be a molded polymer, copolymer or blends and derivatives thereof, ormay comprise metal, or combinations thereof, or other materials that arecapable of providing sufficient moisture resistance.

The dose container disk 30 can have an outer diameter of between about50-100 mm, typically about 65 mm and a thickness (FIG. 9) of betweenabout 2-5 mm, typically about 3 mm. The disk 30 can comprise a cyclicolefin (COC) copolymer. The apertures 30 a can have a diameter ofbetween about 2-5 mm, typically about 3 mm and the sidewalls 30 w of thedose containers 30 c may have an angle or draft of about 1-3 degrees perside, typically about 1.5 degrees, as shown in FIG. 3D, to facilitateremoval from a mold (where a molding process is used to form the disk30). The dose container 30 is configured to be able to protect thepowder from moisture ingress, while providing a desired number of dosesin a compact overall inhaler size. The individual doses 30 c are spacedapart from each other to allow sufficient seal area and materialthickness for moisture protection of the powder.

Similar to the embodiment shown in FIG. 2E, FIG. 3C illustrates that thedose containers 30 c may be defined by apertures 30 a sealed by sealantlayers 36, 37 over and under the apertures 30 a. The sealant can includefoil, a polymer and/or elastomer, or other suitable materials orcombinations of materials, including laminates. In a dry powdermedicament inhaler 10, the drug powder is stored in a closed,moisture-resistant space provided by the dose containers 30 c.

Embodiments of the invention provide a dose container assembly 20 thatcan provide a suitable seal and facilitate attachment of the airwaydisks 40, 50 to the dose ring or disk 30. In some embodiments, the dosecontainer disk 30 contains sealants 36, 37 which may be a continuouslayer over the upper and lower (primary) surfaces of the dose disk 30and the upper and lower airway disks 50, 40 can contact the respectivesealant and abut the dose disk to allow for a tight fit. The exemplaryattachment features shown in FIG. 2E can reduce air leakage by allowinga close fit of the airway disks 40, 50 to the dose ring 30. The disks40, 50 can sandwich the dose ring 30 and the dose ring can act as the“stop” to set the depth of engagement of the assembly features on theairway disks 40, 50. Embodiments of the invention provide a feature toindex the airway disks 40, 50 relative to the dose ring 30, and somesimple frictional engagement members, such as, but not limited to,“crush ribs”, on one or both of the airway disks 40, 50 to secure theirattachment to each other as will be discussed further below.

FIG. 4A illustrates an example of a lower airway disk 40. As shown, thedisk 40 defines a plurality of circumferentially spaced apart channels41. For the staggered concentric dose container configuration, the disk40 can include alternating long and short airway channels 42, 43,respectively. Each channel 41 includes opposing end portions 41 a, 41 b,one (substantially or entirely) closed end portion 41 a typicallypositioned adjacent the dose container 30 c and one open end portion 41b. The open end portion 41 b can merge into and/or is positionedadjacent the exit port 10 p and/or mouthpiece 10 m (FIGS. 7A-7C). Theintake and flow can be in either direction and the open end 41 b can beconfigured to face either the inner or outer perimeter of the disk 40(e.g., be either positioned radially innermost or radially outermost onthe disk 40). The channels 41 include upwardly extending sidewalls 41 wwith adjacent pairs of the long and short channels sharing one of thesidewalls 41 w. Optionally, as shown by the broken line with respect tofeature 48 in FIG. 4A, the channels 41 can include a small bleed hole 48that allows air to enter but is sized to inhibit dry powder from exitingtherefrom (the bleed holes 48 are shown only with a few of the channels41 for ease of illustration).

FIGS. 4A and 4B illustrate that the disk 40 can includecircumferentially spaced apart upwardly extending tabs 47, one of whichincludes the radially extending tab 45 discussed above. The disk 40 canalso include circumferentially extending recesses 49 which align withtabs on the upper airway disk 50 to sandwich the dose disk therebetween.The tabs 47 can include crush ribs 47 r that matably engage with tabs 57on the upper airway disk 50 (FIG. 5A) to hold the three piece assembly20 with sufficient force without requiring any additional attachmentmeans.

FIG. 4C illustrates that the disk 40 can also include dose indicia 44 sothat a user can visually note what dose is being dispensed or a numberof doses left in the inhaler. The dose indicia 44 can align with a dosereading aperture in the inhaler housing so that a user can visuallyassess the dose indicia/information that is visible to a user when arespective dose is indexed or is next to be indexed, to the dispensingposition. Dose indicia 44 may also or alternatively be placed on theupper disk 50 and aligned with a dose reading aperture (not shown), oron both disks (also not shown). FIG. 14C illustrates that dose indiciamay be placed along the outer perimeter edge of the lower surface of thelower disk 40, and numbered sequentially 1-60, but other patterns may beused, depending on the opening sequence (and the number of doses on thedisk). In some embodiments, the dose indicia numbering can seriallyprogress to alternate between rows of the dose containers 30 where thedose containers are opened in sequence in alternate rows, e.g., number 1on the outer row, number 2 on the inner row, number 3 on the outer row(or vice versa) and so on. However, other dose numbering patterns may beused, depending on the opening sequence (and the number of doses on thedisk). That is, this numbering may be appropriate where the inhaler isconfigured to open a dose container in one row, then open an adjacentdose container in the other row (e.g., inner to outer ring or outer toinner ring of dose containers), and repeating this sequence serially,where two rows of dose containers are used. However, other embodimentsmay open all the inner dose containers or all the outer dose containers,then open the dose containers in the other row or use a differentalternating pattern of opening the dose containers on the inner andouter rows, and the dose numbering indicia on the disk 40 and/or 50 canbe presented accordingly.

FIG. 5A illustrates an example of an upper airway disk 50. In thisembodiment, the upper airway disk 50 is shown inverted from its normaluse position (and inverted relative to the orientation shown in FIG.2A). As shown, the disk 50 defines a plurality of circumferentiallyspaced apart channels 51. For the staggered concentric dose containerconfiguration, the disk 50 can include alternating long and short airwaychannels 52, 53, respectively. Each channel 51 includes opposing endportions 51 a, 51 b, the closed or substantially closed portion 51 a istypically positioned adjacent the dose container 30 c. The intake andflow can be in either direction and the open end 51 b can be configuredto face either the inner or outer perimeter of the disk 50 (e.g., beeither positioned radially innermost or radially outermost). The other(open) end portion 51 b merges into and/or is positioned adjacent theexit port 10 p and/or mouthpiece 10 m (FIGS. 7A-7C) and/or make-up airport or channel. The channels 51 include outwardly extending sidewalls51 w with adjacent pairs of the long and short channels sharing one ofthe sidewalls 51 w. Optionally, the channels 51 can include a smallbleed hole 48 (shown with only one channel for ease of illustration)that allows air to enter but is sized to inhibit dry powder from exitingtherefrom.

As also shown in FIG. 5A, each channel 51 can include an aperture 55that is configured to reside over a respective dose container 30 c withthe upper sealant layer 36 of the dose container 30 c residing under theaperture 55. The apertures 55 allow a piercing (e.g., slicing orpuncturing) member (e.g., 220 a, 220 b, FIG. 10A) to extend through theaperture 55 and open the sealant layers 36, 37 (FIG. 3C). As shown inFIG. 5A, the upper disk 50 can also include one or more of indexing ribs58 and/or inner perimeter gear teeth 60 or other features that can indexthe disk within the inhaler to rotate the disk to provide the differentdose containers 30 c to a dispensing position and/or position a piercingmechanism over the target dose container for dispensing to open the dosecontainer 30 c. In other embodiments, one or both of these rotating andpositioning mechanisms (or different features) can be provided on thelower disk 40 or the dose disk 30.

FIG. 5B illustrates that the disk 50 can include three tabs 57 insteadof four as shown in FIG. 5A (the lower airway disk 40 can also includethree tabs instead of four in this embodiment, see FIGS. 4B, 4C). One ofthe tabs 57 can have a vertically extending orientation rib 56, shown onan inner perimeter surface of the tab 57. In some embodiments, theorientation rib 56 on the upper disk 50 cooperates with a piercing frameassociated with the piercing mechanism fixed in the inhaler housing sothat the orientation rib 56 aligns to the frame to set a correct initialposition according to dose number (e.g., 1) and prevents indexing pastthe number of doses in the disk assembly 20. Stated differently, theorientation rib 56 cooperates with the inhaler housing to set an initialposition of the disk assembly 20 and also stops the disk assembly 20from rotating around more than once.

FIG. 5B also illustrates that the apertures 55 can be configured with ageometry that corresponds to the shape of the piercer 220. The apertures55 can be configured to closely surround the piercer 220. The piercer220 can be a fluted piercer. As shown, the aperture 55 has three lobes55 l to snugly matably receive a correspondingly shaped three lobe(fluted) piercer 220 (FIG. 19D). The fluted piercer can have othernumber of lobes, such as, for example four circumferentially spacedapart lobes, as shown in FIG. 19F and the apertures 55 can have acorresponding four lobe shape. The lobes 55 l can be in a differentorientation in the inner row versus the outer row, e.g., rotated 180degrees.

FIGS. 2A and 6 illustrate the dose container assembly 20 integrallyattached together. FIGS. 2B, 4A, and 5A illustrate the exemplary diskcomponents, 30, 40, 50. The tabs 57 of the disk 50 fit into spaces 49 ofthe disk 40 and the tabs 47 of the disk 40 fit into spaces 59 of thedisk 50 with the crush ribs 47 r firmly abutting the outer edges of tabs57 to frictionally engage the components together with the dose disk 30sandwiched therebetween with a flush fit via a relatively easy“press-fit” assembly method. The dose container disk 30 is aligned withthe upper and lower airway disks 50, 40 via the (radially outwardextending) tab 45 that engages one of the alignment notches 34 of thedose container ring 30 as discussed above. However, other alignmentfeatures or indicia may be used as well as other attachmentconfigurations.

The upper and lower airway disks 50, 40 (where both are used) can beattached to the dose container disk 30 so as to reduce any gaps in theairway path defined thereby. The disk 30 can be a stop for attachmentfeatures on the airway disks 40, 50. The disk 30 with the sealants 36,37 can have substantially planar upper and lower primary surfaceswithout requiring any attachment features. The lower portion of theupper airway disk 50 and the upper portion of the lower airway disk 40can snugly reside against the respective opposing primary surfaces ofthe dose container disk 30 so that the attachment features/componentsare only on the upper and lower disks 50, 40 allowing for a snug andsufficiently air-tight interface between the disks 30, 40, 50 withoutgaps created by tolerances in other build configurations. The press-fitattachment without use of adhesives while providing for thesubstantially air-tight interface can be advantageous andcost-effective. However, as noted above, other attachment configurationsmay be used, including, for example, ultrasonic welding, adhesive, laserweld, other friction fit and/or matable configurations, the use of seals(O-rings, gaskets and the like) between the connection regions of thewalls of the airway channels facing the dose container 30 c and thesealant layers 36, 37 over and/or under the dose containers 30 c of thedisk, including combinations thereof, and the like.

As shown in FIGS. 7A-7C, in operation, pairs of upper and lower alignedchannels 41, 51 can reside over and under a respective dose container 30c and are in fluid communication via the opened dose container 30 c andaperture 30 a. That is, as shown in FIG. 7A, a piercing member 220advances to pierce the upper and lower sealant layers 36, 37,respectively (FIG. 3C). The piercing member 220 can be configured toextend and remain in the lower airway channel or may (partially orfully) retract before dispensing after opening the lower sealant. Also,although shown as extending down to pierce the sealant layers, thepiercing member 220 can be configured to extend upward from the bottom.Either way, the piercing member 220 can be configured to occlude theaperture 55 in the upper (or lower disk).

As shown in FIG. 7B, the piercing member 220 can then partially or fullyretract, or stay extended in the lower (or upper) airway channel,depending on the configuration of the mechanism, but is typicallyconfigured to plug and/or cooperate with a member that can plug theaperture 55 of the upper disk 50 (or lower disk 40 if piercing from thebottom) or otherwise occlude this passage so that the piercing member220 and/or cooperating member substantially blocks, occludes (and/orseals) the aperture/opening 55 (FIGS. 2A, 5A, 5B). In this way, if theinhaler is inverted, powder is prevented from spilling out of thechannel 51 because of the blockage provided by the piercing member 220.The airflow path 10 f may be any direction from above to below the dosecontainer 30 c or vice versa or from the inner perimeter to the outer orvice versa, shown for example only in FIG. 7B by the arrow to allow airto flow through the bottom channel up through the aperture 30 a and outthe top channel 51 to the mouthpiece 10 m. It is also noted that theexit or open end portion of the channel 41 b, 51 b may face the innerperimeter rather than the outer perimeter of the disc assembly 20.

After dispensing, the piercing member 220 is fully retracted as shown inFIG. 7C and the dose container assembly 20 can be rotated to adispensing position and/or the piercing member 220 can be activated toopen a different dose container 30 c. In operation, the dose containerassembly 20 can be radially pushed outward to seal or provide a snugexit path for the airway channel 41 and/or 51 against the mouthpiece 10m. A seal, such as an O-ring may be used to provide a sufficientlyair-tight path between the airflow exit path and the disk assembly 20.Other airpath seal or closure configurations may be used.

FIGS. 8A, 8B and 9 illustrate an example of a dose container disk orring 30 with two rows of apertures 30 a used for dose containers 30 c.The dose container disk 30 can be relatively thin, such as about 2-4 mmthick. The dose container apertures 30 a can be configured so that theinner row 32 is at least about 2 mm from the outer row 31 and so thatthe inner and outer rows of dose containers are spaced inward from therespective perimeters by about 2 mm. This spacing can provide sufficientmoisture permeability resistance and/or oxygen resistance.

FIG. 10A is a cutaway, partial perspective view of an inhaler 10,according to some embodiments of the present invention. A dose containerassembly 20, including a dose container disk 30 and upper and lowerairway disks 40, 50, is rotatably secured within the inhaler housingportions 12, 13. As described above with respect to FIGS. 3A and 3C, thedose container disk 30, in some embodiments, has opposing upper andlower primary surfaces, a first row of circumferentially spaced apartdose containers 30 c at a first radius and a second row ofcircumferentially spaced apart dose containers 30 c at a second radiusso that the first and second rows are concentric with respect to acenter of the disk 30. The dose containers 30 c contain dry powdertherein and are defined by apertures 30 a, which can be sealed bysealants 36, 37 over and under the apertures 30 a. In some embodiments,however, a dose container disk 30 may have a solid bottom with onesealant overlying dose container apertures, as would be understood bythose skilled in the art.

As shown in FIG. 10A, in some embodiments the inhaler 10 includes areciprocating dual piercing mechanism 200 that is mounted to a piercingframe 300 and which is controlled by a rotatable ramp disk 400. Theinhaler 10 also includes an indexing mechanism 500 for rotating the diskcontainer assembly 20. The piercing mechanism 200 is operably associatedwith the dose container assembly 20 and is configured to pierce thefirst and second sealants 36, 37 that seal a dose container 30 c. Thepiercing mechanism 200 includes two piercing members 220 a, 220 b thatare configured to pierce the sealants 36, 37 over and under dosecontainers 30 c in the respective two rows of dose containers 30 c. Forexample, the first piercing member 220 a is configured to pierce thesealants 36, 37 over and under dose containers 30 c in a first row ofdose container apertures 30 a, and the second piercing member 220 b isconfigured to pierce the sealants 36, 37 over and under dose containers30 c in a second row of dose container apertures 30 a. Each piercingmember 220 a, 220 b includes a distal piercing end 221 and a proximalend 222.

FIG. 10B is a cutaway, partial perspective view of an inhaler 10according to other embodiments of the present invention. The inhaler 10illustrated in FIG. 10B incorporates the ramp disk 400 of FIGS. 11B, 13Band 13C, and the piercing frame 300 of FIG. 16B, which are describedbelow.

Referring now to FIGS. 11A-11C, 12A-12B, and 13A-13C, the piercingmechanism 200 and components operably associated therewith in variousembodiments of the present invention are illustrated. FIG. 11A is a topperspective view of the inhaler of FIG. 10A with the cover 11 and upperand lower housing portions 12, 13 removed. In the illustratedorientation, a ramp disk 400 overlies a piercing frame 300, and thepiercing frame 300 overlies the dose container assembly 20. An actuatormechanism 306 is rotatably secured to the piercing frame 300 and isoperably associated with the ramp disk 400 to rotate the ramp disk 400so as to selectively move each of the piercing members 220 a, 220 b ofthe piercing mechanism 200 between .respective piercing and retractedpositions, and more specifically, between respective piercing positions,partially retracted positions, and fully retracted positions.

FIG. 11B is a top perspective view of the inhaler of FIG. 10B with thecover 11 and upper and lower housing portions 12, 13 removed andillustrating the ramp disk 400 of FIGS. 13B and 13C. FIG. 11C is a topplan view of the inhaler of FIG. 10B, with the cover 11 displayedtransparently and with some elements displayed in broken line forclarity, and illustrating ratchet arms 12 a in the upper housing portion12 cooperating with teeth 400 t in the first side 402 of the ramp disk400. The cooperation of ratchet arms 12 a and teeth 400 t serve ananti-backup function similar to that described with respect to backupposts 350 and catches 420, illustrated in FIGS. 12A and 13A, whichprevent backward rotation of the ramp disk 400, as described below.

FIG. 12A is a top perspective view of the piercing frame 300 for theinhaler 10 of FIG. 10A with the ramp disk 400 removed therefrom for easeof discussion and clarity. As shown, the piercing frame 300 has asubstantially planar surface 302 with a centrally located, upwardlyextending post 304. A user-accessible actuator mechanism 306 that isconfigured to rotate the ramp disk 400, as will be described below, isrotatably secured to the piercing frame 300. The illustrated actuatormechanism 306 includes first and second ring members 308, 310 connectedby radially extending members 312 so as to be substantially concentric.The first ring member 308 is rotatably coupled to the post 304 such thatthe actuator mechanism 306 rotates about axis A₁ between a firstposition (FIG. 1B) and a second position (FIG. 1C), as will be describedbelow.

The actuator mechanism 306 includes a plurality of spaced-apart, arcuatearms 314 positioned between the first and second ring members 308, 310,as illustrated in FIG. 12A. Each arcuate arm 314 has a proximal end 314a secured to the first ring 308 and a distal free end 314 b. The distalfree end 314 b of each arcuate arm 314 includes a pawl 316 that isconfigured to engage spaced-apart step members 414 (FIG. 13A) on theramp disk 400 to cause one way rotation of the ramp disk 400, as will bedescribed below.

The illustrated actuator mechanism 306 also includes an arcuate bodyportion 318 that extends radially outward from the second ring member310. The arcuate body portion 318 includes user lever 320 that extendsoutwardly from the inhaler so as to be gripped by a user of the inhaler10. A user moves the actuator mechanism 306 from a first position to asecond position via lever 320 to rotate the ramp disk 400 and pierce adose container 30 c, as will be described below. The configuration ofthe actuator mechanism 306 allows for a relatively short stroke (e.g.,60°) of the lever 320 from the first position (FIG. 1B) to the secondposition (FIG. 1C).

The actuator mechanism body portion 318 is configured to slide along thepiercing frame surface 302 as the actuator mechanism 306 is movedbetween first and second positions. The piercing frame 300 includesfirst and second blocking members 322, 324 that extend upwardly from thepiercing frame surface 302 and that are configured to limit therotational movement of the actuator mechanism 306. For example, when theactuator mechanism 306 is in the first position, end 318 a of thearcuate body portion 318 abuts blocking member 322. When the actuatormechanism 306 is moved to the second position, end 318 b of the arcuatebody portion 318 abuts blocking member 324.

In the illustrated embodiment, the illustrated body portion 318 includesa U-shaped guide 326 that slides along a rail 328 associated with thepiercing frame 300. The guide 326 and rail 328 are designed tofacilitate smooth sliding operation of the actuator mechanism 306between the first and second positions. In addition, the U-shaped guide326 and rail 328 can be configured to block the ingress of foreignmaterial into the inhaler 10, and also to block the visibility ofinternal components of the inhaler 10.

The actuator mechanism 306 can also include a dose container assemblybiasing post 360, as illustrated in FIG. 16A. The post 360 extendsdownwardly from the second ring member 310 of the actuator mechanism 306and through an arcuate slot 362 formed in the piercing frame 300. Thebiasing post 360 is configured to make contact with a tab 530 on anindexing arm 510 of the indexing frame 508 (FIG. 10A) when the actuatormechanism 306 is moved to the second position. The biasing post 360causes the tab 530 to flex against the inner perimeter of the dosecontainer assembly 20 so as to urge the dose container assembly 20toward the mouthpiece 10 m for a tight interface with the dose containerassembly 20 during inhalation.

FIGS. 15B and 16B illustrate an alternate embodiment of a biasingmechanism that can bias the disk assembly 20 toward the mouthpiece 10 mof the inhaler 10 of FIG. 10B during inhalation then releasing ordisengaging to allow rotation of the disk assembly 20 for indexing. Asdiscussed above, in some embodiments, the inhaler 10 can be configuredto rotate the disk assembly 20 a defined angular rotation, such as about6 degrees, to serially dispense or access dose containers alternately oninner and outer rows. This biasing mechanism can be configured tooperate with the lever 320 similar to that discussed above, but may alsobe activated using other components or features.

As shown in FIG. 16B, the biasing mechanism can include a post 360 thatresides proximate an inner perimeter of the dose container disk assembly20. The post 360 can reside in a circumferentially extending slot 362having an end portion that merges into a slot portion 363 that extendsradially outward toward the inner perimeter of the dose disk assembly20. During and/or just prior to release of the medicament to a user forinhalation (e.g., “dosing”), the post 360 travels in slot 362 until itreaches slot portion 363 and pushes (typically indirectly) against theinner perimeter of the disk assembly 20 to bias the disk assembly 20toward the mouthpiece 10 m.

In some embodiments, the post 360 can communicate with a stationary post360 a on the indexing frame 508 (FIG. 15B). In the embodiment shown, thebiasing post 360 is configured to contact and push against post 360 acausing post 360 a to flex radially outward against the dose containerassembly 20. The two posts 360, 360 a can be configured to projecttoward each other, one upwardly and one downwardly, with the post 360 atypically residing closer to an inner perimeter of the dose diskassembly 20.

The post 360 is typically attached to or in communication with the lever320 which is accessible by a user. However, the post 360 can be incommunication with other mechanisms that cause the post 360 to move inthe slot 362 and bias the disk assembly 20 toward the mouthpiece 10 m.As shown in FIG. 15B, the indexing frame 508 can reside under gears 514that are associated with the indexing mechanism 500. The rotatable gears514 can be held on mounts 515 on the piercing frame member 300 as shownin 15C. Generally stated, the gears 514 communicate with teeth 411 onindexing post 410 (that can be part of the ramp disk 400) and gear teeth504 on the disk assembly 20 (e.g., as shown, on the lower disk 40).Turning the indexing post 410 turns gears 514 which, in turn, indexesthe disk assembly 20. The other gear teeth 502 (residing closer to thebottom of the inhaler housing) can communicate with indexing controlarms 512 on the indexing frame 508 as shown in FIG. 14C which can helpmore precisely turn the dose container assembly a desired rotationalamount.

Referring back to FIG. 12A, an arm 330 extends outwardly from the secondring member 310, as illustrated. The arm 330 includes a proximal end 330a attached to the second ring member 310 and a distal free end 330 b.The distal free end 330 b includes a pawl 331 extending therefrom thatengages teeth 332 in a rack 334 attached to the piercing frame 300. Thepawl 331 allows the actuator mechanism 306 to be moved by a user only inone direction from the first position to the second position. The pawl331 prevents backward movement of the actuator mechanism (i.e., in adirection toward the first position) until the actuator mechanism 306reaches the second position. When the actuator mechanism 306 reaches thesecond position, the pawl 331 disengages from the teeth 332 of the rack334 and the actuator mechanism 306 is free to move back to the firstposition while the arm 330 travels over the rack 334. The actuatormechanism 306 is moved back to the first position as a result of a userclosing the cover 11 of the inhaler 10.

In some embodiments, when the pawl 331 is engaged with teeth 332 in therack 334 as the actuator mechanism 306 is moved from the first positionto the second position, the distal free end 330 b of arm 330 is urgedinwardly toward the second ring member 310. When the pawl 331 disengagesfrom the teeth 332, the distal free end 330 b biases outwardly. Thedistal free end 330 b of arm 330 has a tapered configuration such thatwhen the free end 330 b biases outwardly, the tapered configurationcauses the free end 330 b to slide along an outside wall 336 of the rack334 such that the pawl 331 cannot engage any of the teeth 332 when theactuator mechanism 306 is returned to the first position. When theactuator mechanism 306 is in the first position, the taperedconfiguration of the distal free end 330 b of arm 330 causes the pawl331 to again become engaged with the teeth 332 of the rack 334 such thatthe pawl 331 prevents backward movement of the actuator mechanism 306between the first and second positions.

Still referring to FIG. 12A, the reciprocating dual piercing mechanism200 includes an inner or first piercing member 220 a and an outer orsecond piercing member 220 b in adjacent, spaced-apart relationship.Each piercing member 220 a, 220 b is configured to reciprocally movebetween a retracted position and an extended piercing positionindependently of the other. The piercing members 220 a, 220 b aremovably secured to a support structure 224 that extends upwardly fromthe piercing frame 300, as illustrated. A pair of apertures 340 a, 340 bare formed through the piercing frame surface 302, as illustrated. Eachaperture 340 a, 340 b is in alignment with, a respective row of dosecontainers 30 c in the dose container assembly 20. As the dose containerassembly 20 is indexed during use, a respective dose container 30 c inat least one row is positioned under a respective aperture 340 a, 340 bsuch that a respective piercing member 220 a, 220 b can pierce the upperand lower sealant layers 36, 37 of the dose container 30 c.

A biasing element 230, such as a torsion spring, is secured to thepiercing frame 300 and contacts each piercing member 220 a, 220 b andduring operation is configured to urge each piercing member 220 a, 220 bto a retracted position. Although illustrated as a single biasingelement 230, more than one biasing element may be utilized, for example,one or more separate biasing elements for each piercing member 220 a,220 b may be utilized. The configuration of the piercing mechanism 200can allow more flexibility for the design of the spring 230. Forexample, the spring 230 is not required to be positioned under thepiercing members 220 a, 220 b, but can reside laterally or radiallyspaced apart from the piercing members 220 a, 220 b. As such, a devicewith less height requirements than conventional inhaler devices can beachieved.

Each elongate piercing member 220 a, 220 b includes a distal piercingportion 221 (FIG. 10A) and a proximal head portion 222. In someembodiments, the distal piercing portion 221 can be a corkscrew piercerconfigured to pierce the sealants 36, 37 of a dose container 30 c with astraight vertical non-rotational movement, as illustrated and describedwith respect to FIGS. 19A-19B, below. In some embodiments, the distalpiercing portion 221 can be a fluted piercer configured to pierce thesealants 36, 37, as illustrated and described with respect to FIGS.18C-18F. Various types of piercers and various piercer configurationsmay be utilized in accordance with embodiments of the present invention,without limitation.

As will be described below, in some embodiments each piercing member 220a, 220 b partially retracts from a dose container 30 c during a portionof the operation of the inhaler 10 so as to plug the aperture 55 of theupper disk 50 of the inhaler 10 during and/or after drugrelease/inhalation.

As shown in FIG. 12A, in some embodiments, the piercing frame 300 alsoincludes a pair of anti-backup posts 350 in opposing relationship. Eachillustrated anti-backup post 350 includes a radially inwardly extendingtooth 350 a at the post free end, as illustrated. The tooth 350 a ofeach anti-backup post 350 is configured to engage a catch 420 (FIG. 13A)on the ramp disk 400 and prevent backward rotation of the ramp disk 400,as described below.

FIG. 12B is a top perspective view of the piercing frame 300 for theinhaler 10 of FIG. 10B with the ramp disk 400 removed therefrom for easeof discussion and clarity, according to other embodiments of the presentinvention. The illustrated piercing frame 300 of FIG. 12B does notinclude the pair of anti-backup posts 350 illustrated in FIG. 12A.Otherwise, the piercing frame 300 of FIG. 12B is substantially similarin construction and functionality to the piercing frame 300 of FIG. 12A.

Referring now to FIG. 13A, a bottom perspective view of the ramp disk400 for the inhaler 10 of FIG. 10A is illustrated. The ramp disk 400includes opposite first and second surfaces or sides 402, 404 (FIG.11A). The ramp disk 400 includes first and second sets of ramp elements406, 408 that extend outwardly from the second side 404 in staggered,concentric relationship. The ramp disk 400 also includes an indexingpost 410 that extends outwardly from a central portion of the secondside 404. In addition, a ring member 412 extends outwardly from thesecond side 404 between the second set of ramp elements 408 and theindexing post 410.

The ramp elements 406, 408 are typically substantially identical inconfiguration, and each have a substantially curvilinear configuration,as illustrated. Each first (outer) ramp element 406 includes a firstinclined portion 406 a, a plateau portion 406 b, a second inclinedportion 406 c, and a shelf portion 406 d. Similarly, each second (inner)ramp element 408 includes a first inclined portion 408 a, a plateauportion 408 b, a second inclined portion 408 c, and a shelf portion 408d. The first set of ramp elements 406 are configured to engage aproximal end 222 of the outer piercing member 220 b and move (push) theouter piercing member 220 b between retracted and extended (piercing)positions as the ramp disk 400 is rotated in the direction indicated byarrow A₂. The second set of ramp elements 408 are configured to engage aproximal end 222 of the inner piercing member 220 a and move (push) theinner piercing member 220 a between retracted and extended (piercing)positions as the ramp disk 400 is rotated in the direction indicated byarrow A₂. The inner ramp elements 408 are spaced apart from each otherby about one hundred twenty degrees (120°). Similarly, the outer rampelements 406 are spaced apart from each other by about one hundredtwenty degrees (120°).

The first and second sets of ramp elements 406, 408 are angularlyseparated by an angle indicated as A₃. In some embodiments, angle A₃ maybe between about five degrees and fifteen degrees (5°-15°). In someembodiments, angle A₃ may be about eight degrees (8°). Indexing of thedose container assembly 20 (i.e., rotation of the dose containerassembly 20 to position a medicament-containing dose container 30 cbeneath a piercing member 220 a, 220 b) occurs within this incrementindicated by A₃. That is, indexing of the dose container assembly 20occurs when neither ramp elements 406, 408 are in contact with arespective piercing member 220 a, 220 b. Typically, the dose containerassembly 20 cannot be properly indexed (rotated) if a piercing memberresides in a dose container 30 c.

The ring member 412 that extends outwardly from ramp disk side 404includes an outer surface 412 a and an inner surface 412 b, and an endportion 412 c. A diameter of the ring member 412 and a diameter of thesecond ring member 310 of the actuator mechanism 306 (FIG. 12A) aresubstantially the same. Thus, in some embodiments, the end portion 412 cof the ramp disk ring member 412 is in contacting relationship with theouter ring member 310 of the actuator mechanism 306 within the inhaler10.

A plurality of spaced-apart step members 414 extend radially inwardlyfrom the ring member inner surface 412 b, as illustrated in FIG. 13A.Each step member 414 includes an end 414 a and a tapered portion 414 bextending away from the end 414 a. Each end 414 a of a step member 414is configured to be engaged by a pawl 316 at the free end 314 b of anarcuate arm 314 of the actuator mechanism 306 (FIG. 12A). The taperedportion 414 b of each step member 414 allows the pawl 316 to slide alongthe step member 414 and engage .the end 414 a. User movement of theactuator mechanism 306 from the first position to the second positioncauses the ramp disk 400 to rotate along the direction indicated byarrow A₂.

Movement of a piercing member 220 a, 220 b by a respective ramp element408, 406 will now be described with respect to a first ramp element 406and the outer piercing member 220 b. Each of the first and second rampelements 408, 406 cause the same movement of respective piercing members220 a, 220 b. When a user opens the cover 11 of the inhaler 10 to theposition indicated in FIG. 1B, the actuator mechanism 306 is in thefirst position. When the actuator mechanism 306 is in the firstposition, a proximal end 222 of piercing member 220 a is in contact witha shelf portion 408 d of a ramp element 408. As the ramp disk 400 isrotated via user movement of the actuator mechanism 306 in the directionindicated by arrow A₂ (i.e., from the first position to the secondposition), the proximal end 222 of piercing member 220 a no longercontacts the shelf portion 408 d, and the piercing member 220 a is fullyretracted. The dose container assembly 20 is also indexed to the nextdose container 30 c during the rotation indicated by angle A₃ via therotation of the indexing post 410. The first inclined portion 406 a ofthe ramp element 406 then contacts the proximal end 222 of piercingmember 220 b and extends the piercing member 220 b into a dose container30 c. Upon continued movement of the actuator mechanism 306, the plateauportion 406 b is in contact with the piercing member proximal end 222and the piercing member 220 b is at maximum depth within a dosecontainer 30 c. Continued movement of the ramp disk 400 causes thepiercing member proximal end 222 to follow the second inclined portion406 c under the force of spring 230 such that the piercing member 220 bretracts from the dose container 30 c.

When the actuator mechanism reaches the second position, the proximalend 222 of piercing member 220 b is in contact with the shelf portion406 d, which causes the piercing member 220 b to remain partially withinthe aperture 55 of the upper airway disk 50 so as to prevent medicamentfrom falling out of the open dose container 30 c prior to inhalation bya user, as described above with respect to FIGS. 7A-7C. The piercingmember proximal end 222 remains in contact with the shelf portion 406 dof the first ramp element 406 as the cover 11 of the inhaler 10 isreturned to the closed position.

The indexing post 410 includes a plurality of spaced apart ribs 411extending radially outward from the indexing post, as illustrated inFIG. 13A. As described below with respect to FIGS. 14A and 15A, theseindexing post ribs 411 are configured to engage and cause rotation of anidler gear 514 (FIG. 14A) that is operably associated with the indexingmechanism 500. The ramp disk 400 is particularly advantageous becausethe ramp elements 406, 408 that cause piercing and the indexing post 410that causes dose container assembly indexing are located on the sameinhaler component. As such, the timing of dose container piercing anddose container assembly indexing is properly maintained at all times.

The illustrated ramp disk ring member 412 includes a plurality ofanti-backup catches 420 extending from the outer surface 412 a thereofin circumferentially spaced-apart relationship. Each catch 420 includesa recess 420 a that is configured to engage a tooth 350 a of ananti-backup post 350 on the piercing frame. This engagement of ananti-backup post tooth 350 a within a catch recess 420 a prevents theramp disk 400 from rotating in a direction opposite to that indicated byarrow A₂ (i.e., prevents the ramp disk from being rotated in the wrongdirection, particularly when pawl 316 is deflecting over tapered portion414 b).

Referring now to FIG. 13B, a bottom perspective view of the ramp disk400 for the inhaler 10 of FIG. 10B is illustrated. The ramp disk 400 issubstantially similar in construction and functionality to the ramp disk400 of the inhaler 10 of FIG. 10A. The ramp disk 400 includes oppositefirst and second surfaces or sides 402 (FIG. 13C), 404, and includesfirst and second sets of ramp elements 406, 408 that extend outwardlyfrom the second side 404 in staggered, concentric relationship, asdescribed above with respect to FIG. 13A. However, the first and secondsets of ramp elements 406, 408 of FIG. 13B have a slightly differentconfiguration than the first and second sets of ramp elements 406, 408of FIG. 13A. Each first (outer) ramp element 406 includes a firstinclined portion 406 a, a plateau portion 406 b, and a shelf portion 406d similar to the ramp element 406 of FIG. 13A. However, second inclinedportion 406 c is substantially more steeply inclined in FIG. 13B thanthe second inclined portion 406 c of FIG. 13A. This steeper inclinefacilitates faster movement of the piercing member 220 b from anextended (piercing) position to a partially retracted position. Inaddition, ramp element 406 of FIG. 13B includes a raised portion 406 ethat is configured to prevent the piercing member 220 b from slippingoff the shelf portion 406 d.

Similarly, each second (inner) ramp element 408 of FIG. 13B includes afirst inclined portion 408 a, a plateau portion 408 b, and a shelfportion 408 d similar to the ramp element 408 of FIG. 13A. However,second inclined portion 408 c is substantially more steeply inclined inFIG. 13B than the second inclined portion 408 c of FIG. 13A. Thissteeper incline facilitates faster movement of the piercing member 220 afrom an extended (piercing) position to a partially retracted position.In addition, ramp element 408 of FIG. 13B includes a raised portion 408e that is configured to prevent the piercing member 220 a from slippingoff the shelf portion 408 d.

The indexing post 410 includes a plurality of spaced apart ribs 411extending radially outward from the indexing post, as illustrated inFIG. 13B. These indexing post ribs 411 are configured to engage andcause rotation of a pair of idler gears 514 (FIG. 14C) that is operablyassociated with the indexing mechanism 500.

The illustrated ramp disk 400 of FIG. 13B includes alignment apertures430 extending through the ramp disk 400 from the first side 402 to thesecond side 404. These apertures 430 can facilitate automated assemblyand alignment of the ramp disk 400 in the inhaler 10. In addition,because the inhaler 10 of FIG. 10B does not include anti-backup posts350, as illustrated in FIG. 12A, the ramp disk 400 of FIG. 13B does notinclude a plurality of anti-backup catches extending from the outersurface 412 a of ring member 412.

FIG. 13C is a top perspective view of the ramp disk 400 of FIG. 13B thatillustrates teeth 400 t in the first side 402 thereof. Ratchet arms 12 ain the upper housing portion 12 of the inhaler 10 of FIG. 10B areconfigured to engage the teeth 400 t and prevent backward rotation ofthe ramp disk 400 similar to the function of the backup posts 350 andcatches 420 of FIGS. 12A and 13A.

FIG. 14A is a bottom, cutaway perspective view of the inhaler of FIG.10A illustrating the dose disk indexing mechanism 500. The lower disk 40of the dose container assembly 20 includes first and second sets ofinner perimeter gear teeth 502, 504 in vertically stepped relationship,as illustrated. The lower disk 40 also includes a spiral-shaped groove506 that extends circumferentially around the disk 40, as illustrated.An indexing frame 508 includes a plurality of arcuate indexing arms 510circumferentially spaced-apart, as illustrated in FIG. 14A. Eachindexing arm 510 includes a free end 512 with a tooth 512 a. Theindexing frame 508 is positioned relative to the lower disk 40 such thata tooth 512 a at the free end 512 of each indexing arm 510 engages withthe first set of inner perimeter teeth 502. Indexing arms 510 serve asalignment members that assure exact positioning of a dose container 30 crelative to apertures 340 a, 340 b in the piercing frame, and throughwhich piercing members 220 a, 220 b are extended.

FIG. 14C is a bottom, cutaway perspective view of the inhaler of FIG.10B illustrating the dose disk indexing mechanism 500. The indexingmechanism 500 is substantially similar in construction and function asthe indexing mechanism 500 of the inhaler 10 of FIG. 10A with theexception that a pair of idler gears 514 are utilized. These idler gears514 are engaged by and caused to rotate by indexing post ribs 411.

FIG. 14D is an enlarged, partial plan view of the inhaler of FIG. 14Cillustrating a dose window 520 centered over dose indicia that indicatesthat 60 doses are remaining. FIG. 14E is an enlarged, partial plan viewof the inhaler of FIG. 14C illustrating the dose window 520 centeredover dose indicia that indicates that no (zero) doses are remaining. Thedose window 520 includes a post extending therefrom that engages thespiral groove 506 in the lower disk 40. The groove 506 and post areconfigured to maintain the dose window 520 directly over the doseindicia on the lower disk surface 40 a as the dose container assembly isindexed, as is described below.

Referring to FIG. 15A, the indexing frame 508 of the inhaler 10 of FIG.10A is secured to the lower housing portion 13. An idler gear 514 isrotatably secured to the indexing frame 508 and is positioned such thatthe teeth 516 of the idler gear 514 engage the second set of innerperimeter teeth 504 of the lower disk 40. A centrally located post 518extends upwardly from the lower housing portion 13 and is configured toreceive the indexing post 410 of the ramp disk 400. The post 518 servesas an axis of rotation for the ramp disk 400. The indexing post ribs 411are configured to engage the teeth 516 of the idler gear 514 when thepost 518 is inserted within the indexing post 410.

To index the dose container assembly 20 by a predetermined amount, theramp disk 400 is rotated via user movement of the actuator mechanism 306via user lever 320 from the first position to the second position.Rotation of the ramp disk 400 causes the indexing post 410 to rotatewhich, in turn, causes rotation of the idler gear 514. Rotation of theidler gear 514 rotates the dose container assembly a predeterminedamount via the second set of inner perimeter teeth 504 of the lower disk40. According to some embodiments of the present invention, the actuatormechanism 306 is configured to rotate sixty degrees (60°). Thiscorrelates to six degrees (6°) of rotation of the dose containerassembly 20 (i.e., 6° between a dose container in one row and aneighboring dose container in the other row).

The indexing mechanism 500, according to embodiments of the presentinvention, does not require dose container assemblies to have outerperipheral gear teeth. As such, smaller dose container assemblies can beutilized.

Referring back to FIG. 14A, the inhaler 10 includes a dose window 520positioned above the bottom surface 40 a of the lower disk 40. The dosewindow 520 is a separate component from the lower housing portion 13,and is configured to move relative to the lower housing portion 13. Insome embodiments, the dose window 520 may be slidably attached to thelower housing portion 13. The dose window 520 includes an aperture 522through which a user of the inhaler can view dose indicia 524 (FIG. 14B)on the lower disk surface 40 a. The dose indicia 524 indicates thenumber of doses remaining in the inhaler 10. Alternatively, in someembodiments, the dose indicia 524 may indicate the number of doses thathave already been consumed by the user of the inhaler 10. In someembodiments, the aperture 522 includes a transparent cover or lens toprevent the ingress of foreign material and/or to facilitate viewing thedose indicia 524. In some embodiments, a magnifying lens may be utilizedto facilitate user viewing of dose indicia 524.

The dose window 520 also includes a post 526 extending therefrom thatengages the spiral groove 506 in the lower disk 40. The groove 506 andpost 526 are configured to maintain the aperture 522 directly over thedose indicia on the lower disk surface 40 a as the dose containerassembly is indexed. As illustrated in FIG. 14B, the dose containerassembly includes sixty doses and dose indicia 524 includes the numberszero to sixty (0-60). Because of the geometry of the dose containerassembly, a dose container 30 c is located every six degrees (6°)therearound. As such, the numbers “0” and “60” overlap. In order toproperly show sixty (60) doses remaining when the inhaler is first usedand to properly show zero (0) doses remaining when all of the doses inthe inhaler have been consumed, the dose indicia 524 is displayed on thelower disk surface 40 a in a spiral configuration: The spiral groove 506in the lower disk surface 40 a matches the spiral configuration of thedose indicia 524. As such, as the dose container assembly 20 is indexed,the post 526 engaged within the spiral groove 506 maintains the windowaperture 522 centered over the dose indicia 524 at all times.

The post 526 also serves another important function. When all of thedoses within the inhaler 10 have been consumed, the post abuts the endof the spiral groove 506 such that the dose container assembly 20 cannotbe indexed further. As such, the post 526 serves as an “end of life”stop for the inhaler 10.

Referring to FIGS. 15B, 15C the indexing frame 508 of the inhaler 10 ofFIG. 10B is secured to the piercing frame 300. A pair of idler gears 514are rotatably secured to the piercing frame 300 and is positioned suchthat the teeth 516 of the idler gears 514 engage the second set of innerperimeter teeth 504 of the lower disk 40. These idler gears 514 areengaged by and caused to rotate by indexing post ribs 411. To index thedose container assembly 20 by a predetermined amount, the ramp disk 400is rotated via user movement of the actuator mechanism 306 via userlever 320 from the first position to the second position. Rotation ofthe ramp disk 400 causes the indexing post 410 to rotate which, in turn,causes rotation of the idler gears 514. Rotation of the idler gears 514rotates the dose container assembly a predetermined amount via thesecond set of inner perimeter teeth 504 of the lower disk 40. FIG. 15Cis an exploded side perspective view of components of the indexingmechanism of the inhaler of FIG. 10B.

Referring now to FIGS. 17A-17E, operation of the piercing mechanism 200of the inhaler 10 of FIG. 10A is illustrated. In FIG. 17A, a user hasopened the cover 11 and the actuator mechanism is in the first position.The proximal end 222 of the inner piercing member 220 a is resting onthe shelf portion 408 d of a ramp element 408. As such, the innerpiercing member 220 a is partially retracted from a dose container 30 c.In FIGS. 17A-17E, the ramp disk 400 is shown in dotted line for ease ofdiscussion and clarity.

In FIG. 17B, the user is moving the lever 320 of the actuator mechanism306 in the direction (indicated by A₂) of the second position. The pawl316 of each arcuate arm 314 of the actuator mechanism 306 is engagedwith the end 414 a of a respective step member 414 of the ramp disk 400.As such, movement of the actuator mechanism 306 (via lever 320) causesthe ramp disk 400 to rotate along the direction indicated by arrow A₂.At the stage of operation illustrated in FIG. 17B, the inner piercingmember 220 a is fully retracted and the first inclined portion 406 a ofa ramp element 406 is beginning to engage the proximal end 222 of theouter piercing member 220 b. Rotation of the ramp disk 400 causes theindexing post to rotate which, in turn, rotates the idler gear 514which, in turn, indexes the dose container assembly to the next dosecontainer 30 c. Also, at the stage of operation illustrated in FIG. 17B,the pawl 331 of arm 330 is engaged with the teeth 332 of rack 334 toprevent backward movement of the actuator mechanism 306.

In FIG. 17C, the user has continued to move the lever 320 of theactuator mechanism 306 toward the second position, which has continuedrotation of the ramp disk 400. The proximal end 222 of the outerpiercing member 220 b is engaged with the plateau portion 406 b of theramp element 406, such that the outer piercing member 220 b is fullyextended within a dose container 30 c.

In FIG. 17D, the user has moved the lever 320 of the actuator mechanism306 completely to the second position. As illustrated, the end 318 b ofthe arcuate body portion 318 of the actuator mechanism 306 abuts theblocking member 324. In addition, the tooth 350 a of each anti-backuppost 350 is engaged with a respective catch 420 on the ramp disk 400ring member 412 so as to prevent backwards rotation of the ramp disk400. FIG. 17D represents the dosing position. A user at this point wouldinhale a dose from a pierced dose container 30 c. The proximal end 222of the outer piercing member 220 b is engaged with the shelf portion 406d of the ramp element 406.

Also, in FIG. 17D, the pawl 331 has disengaged from the teeth 332 andthe arm distal free end 330 b has biased outwardly to a relaxedposition. As the actuator mechanism 306 is returned to the firstposition (FIG. 17E), the arm free end 330 b is configured to slide alongan outside wall 336 of the rack 334 such that the pawl 331 cannot engageany of the teeth 332.

In FIG. 17E, the actuator mechanism 306 is being returned to the firstposition as a result of the user closing the cover 11. The ramp disk 400does not move during the return of the actuator mechanism 306 to thefirst position. The tapered configuration of the distal free end 330 bof arm 330 causes the pawl 331 to again be ready to engage with theteeth 332 of the rack 334 when the actuator mechanism 306 reaches thefirst position.

The piercing frame 300, actuator mechanism 306, ramp disk 400, piercingmechanism 200, and the various components associated therewith, may beformed from various materials including, but not limited to, polymericmaterials. Because two piercing members 220 a, 220 b are utilized; wear(e.g., caused by lactose in the medicament powder within the dosecontainers 30 c) can be significantly reduced for each piercing member220 a, 220 b. As such, a less expensive material may be utilized for thepiercing members 220 a, 220 b than may otherwise be necessary if only asingle piercing member were to be utilized.

In addition, because the actuator mechanism 306 and the ramp disk 400are separate components, different materials may be utilized for eachone. For example, cosmetic materials may be utilized for the user lever320 of the actuator mechanism 306, while a less cosmetic material may beutilized for the ramp disk 400, which cannot be seen by a user of theinhaler 10.

FIGS. 18A-18C are top, cutaway views, with partial transparent layers ormembers/disks for clarity, of the inhaler 10 of FIG. 10B that illustratean exemplary sequence of operations thereof, according to someembodiments of the present invention. In FIG. 18A, a user is moving thelever 320 of the actuator mechanism 306 in the direction (indicated byA₂) from the first position to the second position, as described above.The pawl 316 of each arcuate arm 314 of the actuator mechanism 306 isengaged with the end 414 a of a respective step member 414 of the rampdisk 400. As such, movement of the actuator mechanism 306 (via lever320) causes the ramp disk 400 to rotate along the direction indicated byarrow A₂. At the stage of operation illustrated in FIG. 18A, the innerpiercing member 220 a is retracted and the first inclined portion 408 aof a ramp element 408 is beginning to engage the proximal end 222 of theinner piercing member 220 a. Rotation of the ramp disk 400 causes theindexing post 410 to rotate which, in turn, rotates the pair of idlergears 514 (FIG. 14C) which, in turn, indexes the dose container assemblyto the next dose container 30 c.

In FIG. 18B, the user has continued to move the lever 320 of theactuator mechanism 306 toward the second position, which has continuedrotation of the ramp disk 400. The proximal end 222 of the innerpiercing member 220 a is engaged with the plateau portion 408 b of theramp element 408, such that the inner piercing member 220 a is fullyextended within a dose container 30 c. In FIG. 18C, the user has movedthe lever 320 of the actuator mechanism 306 completely to the secondposition. The proximal end 222 of the inner piercing member 220 a isengaged with the shelf portion 408 d of the ramp element 408. Also, atthe stage of operation illustrated in FIG. 18A, the ratchet arms 12 a inthe upper housing portion 12 are cooperating with teeth 400 t in thefirst side 402 of the ramp disk 400 to prevent backward movement of theramp disk 400.

FIG. 19A illustrates one embodiment of a piercing mechanism 200 with acorkscrew piercing member 220. In operation the corkscrew piercingmember 220 moves up and down vertically straight, typically withoutrotation, to create a desired opening shape (e.g., circular) through thesealant layers 36, 37. In other embodiments, the corkscrew piercingmember 220 may rotate during extension and/or dispensing. In theembodiment shown, the corkscrew piercing member 220 can remain in thelower channel 41 while the dry powder is dispensed in the airflow pathand the blockage of the aperture 30 a can be provided by a resilientmember 120 that is mounted on the corkscrew piercing member 220 andmoves up and down therewith. The piercing member 220 can have a twostage operation, fully up (for indexing) and fully down. The mostforward portion of the corkscrew piercing member 220 can have a pointwith a configuration that creates a desired cutting configuration intothe sealant (e.g., foil). In some embodiments, the corkscrew piercingmember 220 can cut a shape with a tab into the sealant 36, 37, then foldthe tab down to release the dry powder. Positioning the corkscrewpiercing member 220 in the channel 41 during dispensing may provideimproved aerodynamics or shear or impaction flow turbulence for the drypowder. The resilient member 120 can comprise a foam block or otherresilient member 120 (such as a hard or rigid member biased by a spring)that can be used to seal or plug the aperture 30 a in disk 30.

FIG. 19B illustrates a similar corkscrew piercing member 220 that isused with a disk assembly 20 having both upper and lower airway disks50, 40. A resilient and/or flexible member 200 p such as a polymericand/or elastomeric or foam plug can be used to occlude or seal theairway disk aperture 55. Such a resilient and/or flexible member 200 pmay also be used with other types of piercing members (e.g., solidpiercing members, fluted piercing members, etc.

FIGS. 19C and 19D illustrate a piercing mechanism 200 with a flutedsolid piercing member 220. The flute may have a straight fluteconfiguration or the flute can have a twist or partial twist along itlength, e.g., the maxima and minima of the lobes change axially alongthe length of the flute. The flute can have a cross section with aplurality of lobes, typically three or four lobes, shown as three lobesin FIGS. 19C and 19D, and as four lobes in FIG. 19F. The flutedconfiguration may extend only a partial forward length and merge into aconstant diameter segment that resides in and helps occlude or seal theaperture 55 as shown in FIG. 19E. In other embodiments, the solid orfluted piercer configuration can merge into a cap or plug that residesover and/or in the aperture 55. In some embodiments, the twisted flutepiercing member 220 can remain in the lower disk 40 during dispensingwhich may facilitate turbulence and/or compaction in the airway.

FIG. 19D illustrates that the fluted piercing member 220 can rotate asit pierces the foil or other sealant material to form a round hole ormay be extended straight without rotation. In other embodiments, thefluted piercer 220 can be extended or advanced without rotation topierce the sealant layer(s) 36, 37. FIG. 19E illustrates that the flutedpiercing member 220′ can include a fluted forward portion 220 f with alength “L₁” that merges into a solid portion 112 that can have asubstantially circular cross-section with a length “L₂”. L₁ is typicallylonger than L₂. L₁ can have a length sufficient to allow the forwardfluted portion 220 f to reside in the dose container aperture 30 a(typically just below the lower sealant line or in-line with or slightlyabove or below the lower surface of the disk 30) and/or through thelower sealant 37 at the same time, with the solid portion engaging theairway disk aperture 55.

The inhaler 10 can have a body that is a portable, relatively compact“pocket-sized” configuration. In some embodiments, the inhaler body canhave a width/length that is less than about 115 mm (about 4.5 inches),typically less than about 89 mm (about 3.5 inches), and athickness/depth of less than about 51 mm (about 2 inches), typicallyless than about 38 mm (about 1.5 inches). The inhaler body can also beconfigured to be generally planar on opposing primary surfaces tofacilitate pocket storage.

The inhaler can include a circuit that can control certain operations ofthe inhaler 10. The inhaler 10 can include a computer port (not shown).The port may be, for example, an RS 232 port, an infrared dataassociation (IrDA) or universal serial bus (USB), which may be used todownload or upload selected data from/to the inhaler to a computerapplication or remote computer, such as a clinician or other site. Theinhaler 10 can be configured to via a wired or wireless communicationlink (one-way or two-way) to be able to communicate with a clinician orpharmacy for reorders of medicines and/or patient compliance. Theinhaler 10 may also include a second peripheral device communicationport (not shown). The inhaler 10 may be able to communicate via theInternet, telephone, cell phone or other electronic communicationprotocol.

In some embodiments, the circuit can include computer program codeand/or computer applications that communicate additional data to a user(optionally to the display) as noted above and/or communicate withanother remote device (the term “remote” including communicating withdevices that are local but typically not connected during normalinhalant use).

In some embodiments, the circuit can be in communication with a vibratordevice (not shown). The vibrator device can be any suitable vibratormechanism. The vibrator device can be configured to vibrate the drypowder in the airflow path. In some embodiments, the vibrator device cancomprise a transducer that is configured to vibrate the openedcartridge(s) holding the dry powder. Examples of vibrator devicesinclude, but are not limited to, one or more of: (a) ultrasound or otheracoustic or sound-based sources (above, below or at audible wavelengths)that can be used to instantaneously apply non-linear pressure signalsonto the dry powder; (b) electrical or mechanical vibration of the walls(sidewalls, ceiling and/or floor) of the inhalation flow channel, whichcan include magnetically induced vibrations and/or deflections (whichcan use electromagnets or permanent field magnets); (c) solenoids,piezoelectrically active portions and the like; and (d) oscillating orpulsed gas (airstreams), which can introduce changes in one or more ofvolume flow, linear velocity, and/or pressure. Examples of mechanicaland/or electro-mechanical vibratory devices are described in U.S. Pat.Nos. 5,727,607, 5,909,829 and 5,947,169, the contents of which areincorporated by reference as if recited in full herein. Combinations ofdifferent vibrating mechanism's can also be used.

In some embodiments, the vibrator device can include a commerciallyavailable miniature transducer from Star Micronics (Shizuoka, Japan),having part number QMB-105PX. The transducer can have resonantfrequencies in the range of between about 400-600 Hz.

In certain embodiments, the inhaler 10 can include visible indicia(flashing light or display “error” or alert) and/or can be configured toprovide audible alerts to warn a user that a dose was properly (and/orimproperly) inhaled or released from the inhaler. For example, certaindry powder dose sizes are formulated so that it can be difficult for auser to know whether they have inhaled the medicament (typically thedose is aerosolized and enters the body with little or no taste and/ortactile feel for confirmation). Thus, a sensor (not shown) can bepositioned in communication with the flow path in an inhaler andconfigured to be in communication with a digital signal processor ormicrocontroller, each held in or on the inhaler. In operation, thesensor can be configured to detect a selected parameter, such as adifference in weight, a density in the exiting aerosol formulation, andthe like, to confirm that the dose was released.

The sealed dose containers 30 c can be configured so that the watervapor transmission rate can be less than about 1.0 g/100 in²/24 hours,typically less than about 0.6 g/100 in²/24 hours and an oxygentransmission rate that is suitable for the dry powder held therein. Thedose container assemblies 20, 20′ can be configured with a stable shelflife of between about 1-5 years, typically about 4 years.

The dose containers 30 c can have a volume (prior to filling andsealing) that is less than about 24 mm³, typically between 5-15 mm³. Thepowder bulk density can be about 1 g/cm³ while the power nominal densitywhen filled (for reference) can be about 0.5 g/cm³. The maximumcompression of a drug by filling and sealing in the dose container 30 ccan be less than about 5%, typically less than about 2%. The maximumheating of drug during the filling and sealing can be maintained to adesirable level so as not to affect the efficacy of the drug or theformulation.

FIG. 20 illustrates the substantially U-shaped airpaths created by thedisk assembly 20 (e.g., the upper disk channel 51 and lower disk channel41 define the long sides of the “U” which extend in a radial directionacross the disk body. As shown, in this embodiment, the outer perimeterof the disk assembly 20 holds both the outlet and an inlet for theairflow path 10 f. The “U” shaped flow path (or, in some embodiment, apartial “U” where only a one of the airflow disks 40, 50 is used) canfunction as a powder deagglomerator. The dry powder particles 10 dimpact the opposing wall of the airway disk channel 51 as they exit thedose container 30 c with sufficient force to deagglomerate the drugpowder.

FIG. 20 also illustrates an example of dry powder particle trajectories10 d entrained in air flow associated with the inspiratory airflow path10 f. After the dry powder exits the dose container 30 c in the airflowpath 10 f, the air flow and smaller powder particles (10 f) in the airare able to make the about 90 degree turn while heavier dry powderparticles (10 d) bounce off the inner wall 51 w of the upper airway diskchannel 51 with increasingly shallow angles eventually going more orless straight out of the mouthpiece 10 m. The impact of the heavier drypowder against the walls 51 w help deagglomerate the dry powder.Referring again to FIG. 5A, in the dual row dose container 30embodiment, the channels 51 vary in length depending on if the dosecontainer 30 is on the inner or outer row.

In some particular embodiments, the airway channels 41, 51 can includealternating short and long channels (see, e.g., FIG. 5A). The length ofthe long channel (the channels with the dose container on the innerperimeter where the outer perimeter is the exit location and vice versaif the inner perimeter is the exit location) can between about 5 mm toabout 15 mm, typically about 10 mm, the length of the short channel canbe between about 3-10 mm, typically about 5 mm (e.g., about 40-70% thelength of the long channel. The depth (vertical height) of each channel41, 51 can be the same or can, in some embodiments vary. Exemplarydepths of the channels 41, 51 are between about 1 mm to about 3 mm,typically about 2 mm, but other depths can be used.

Certain embodiments may be particularly suitable for dispensingmedication to respiratory patients, diabetic patients, cystic fibrosispatients, or for treating pain. The inhalers may also be used todispense narcotics, hormones and/or infertility treatments.

The foregoing is illustrative of the present invention and is not to beconstrued as limiting thereof. Although a few exemplary embodiments ofthis invention have been described, those skilled in the art willreadily appreciate that many modifications are possible in the exemplaryembodiments without materially departing from the teachings andadvantages of this invention. Accordingly, all such modifications areintended to be included within the scope of this invention as defined inthe claims. The invention is defined by the following claims, withequivalents of the claims to be included therein.

That which is claimed is:
 1. A dry powder inhaler, comprising: a dosecontainer disk having a plurality of circumferentially spaced apart drypowder dose containers arranged in first and second concentric rows ofdifferent radius; and a piercing mechanism configured to sequentiallyopen a dry powder dose container on the first row then open a dry powderdose container on the second row multiple times to dispense dry powderfor inhalation.
 2. The dry powder inhaler of claim 1, wherein thepiercing mechanism comprises: first and second elongate piercing membersin adjacent radially spaced-apart relationship, wherein each piercingmember is capable of reciprocal movement between piercing andnon-piercing positions, wherein each piercing member includes a distalpiercing portion and a proximal head portion, wherein the first piercingmember is configured to pierce the sealant of a dose container in thefirst row, and wherein the second piercing member is configured topierce the sealant of a dose container in the second row.
 3. The drypowder inhaler of claim 1, further comprising: a housing, wherein thedose container disk is rotatably secured within the housing, wherein thedose container disk has opposing upper and lower primary surfaces, afirst row of circumferentially spaced apart apertures associated withdose containers at a first radius and a second row of circumferentiallyspaced apart apertures associated with dose containers at a secondradius so that the first and second rows are concentric with respect toa center of the disk, wherein the dose containers have dry powdertherein; and a flexible sealant residing over at least one of the dosecontainer disk upper and lower primary surfaces; wherein the piercingmechanism is operably associated with the dose container disk and isconfigured to pierce the sealant of a dose container in the first row,then pierce the sealant of a dose container in the second row.
 4. Thedry powder inhaler of claim 2, wherein the piercing mechanism comprisesa biasing member configured to urge each piercing member toward aretracted position.
 5. The dry powder inhaler of claim 2, furthercomprising a rotatable ramp disk that comprises first and second sets ofcircumferentially spaced-apart ramp elements in staggered, concentricrelationship, wherein the first set of ramp elements move the firstpiercing member between retracted and extended positions, and whereinthe second set of ramp elements move the second piercing member betweenretracted and extended positions.
 6. The dry powder inhaler of claim 5,wherein each ramp element in the first and second sets comprises a firstinclined portion, a plateau portion, a second inclined portion, and ashelf portion.
 7. The dry powder inhaler of claim 5, further comprisingan actuator that is movable between first and second positions, whereinthe dose container disk has a sealant over an upper primary surfacethereof and a sealant over a lower primary surface thereof, whereinmovement of the actuator from the first position to the second positioncauses the ramp disk to rotate such that a ramp element in the first setcauses the first piercing member to pierce the sealants over and under adose container in the first row.
 8. The dry powder inhaler of claim 7,wherein subsequent movement of the actuator from the first position tothe second position causes the ramp disk to rotate such that a rampelement in the second set causes the second piercing member to piercethe sealants over and under a dose container in the second row.
 9. Thedry powder inhaler of claim 5, further comprising an actuator that ismovable between first and second positions, wherein the dose containerdisk has a sealant over an upper primary surface thereof and a sealantover a lower primary surface thereof, wherein movement of the actuatorfrom the first position to the second position causes rotation of theramp disk which causes one of the first or second piercing members topierce the sealants over and under a dose container, and then partiallyretract therefrom.
 10. The dry powder inhaler of claim 1, furthercomprising an actuator that is movable between first and secondpositions, wherein movement of the actuator from the first position tothe second position causes the dose container disk to sealably engage aninterface or wall associated with an exit airflow path in the inhaler.11. The dry powder inhaler of claim 10, wherein the actuator comprises abiasing post, and wherein movement of the actuator from the firstposition to the second position causes the biasing post to urge the dosecontainer disk to sealably engage an interface or wall associated withan exit airflow path in the inhaler.
 12. The dry powder inhaler of claim1, wherein the first row of dose container apertures have centerlinesthat are circumferentially spaced apart from centerlines of the secondrow of dose containers.
 13. The dry powder inhaler of claim 1, whereinthere are 30 dose container apertures in the first row and 30 dosecontainer apertures in the second row.
 14. The dry powder inhaler ofclaim 3, wherein each piercing member comprises a corkscrew piercerconfigured to pierce the sealant with a straight vertical non-rotationalmovement.
 15. The dry powder inhaler of claim 3, wherein each piercingmember comprises a fluted piercer configured to pierce the sealant. 16.The dry powder inhaler of claim 15, wherein the fluted piercer comprisesthree or four lobes.
 17. The dry powder inhaler of claim 1, wherein eachdose container comprises a dry powder having a pharmaceutically activeagent selected from the group consisting of bronchodilators, inhaledcorticosteroids (ICS), and anticholinergics.
 18. The dry powder inhalerof claim 1, wherein each dose container comprises a dry powder having apharmaceutically active agent, and wherein the agent comprises one ormore of the following bronchodilators: albuterol, salmeterol, ephedrine,adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol,phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol,terbutaline, isoetharine, tulobuterol, or (−)-4-amino-3,5-dichloro-{acute over (α)}-[[6-[2-(2-pyridinyl)ethoxy]hexyl]methyl]benzenemethanol; wherein the bronchodilator may be used in the form ofsalts, esters or solvates to thereby optimize the activity and/orstability of the medicament.
 19. The dry powder inhaler of claim 1,wherein each dose container comprises a dry powder having apharmaceutically active agent, and wherein the agent comprises one ormore of the following inhaled corticosteroids: beclomethasonedipropionate, fluticasone propionate, flunisolide, budesonide,mometasone furoate, and triamcinolone acetonide.
 20. The dry powderinhaler of claim 1, wherein each dose container comprises a dry powderhaving a pharmaceutically active agent, and wherein the agent comprisesone or more of the following anticholinergics: ipratropium, tiotropium,atropine, and oxitropium.